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Abstract 
The spread of cholera is always associated with contaminated food or water 
and this is the reason this disease has been endemic in developing countries 
for centuries due to their lack of proper sanitation facilities and poor or no 
infrastructure for sewage systems. Cholera can spread quickly and 
sporadically after any natural disaster that destroys the sewage system or 
safe drinking water supply of both developed and undeveloped countries. In 
Southeast Asia in December 2004 and in Pakistan and Haiti 2010, cholera 
outbreaks followed the natural disasters; with most of the cholera victims 
being children. Although it is known that the best way to prevent cholera 
outbreak is the development of the infrastructure, provision of a safe drinking 
water supply and proper sanitation, this is a very long-term process, and most 
of the developing countries cannot afford such improvements. These 
situations can be made worse by natural disasters. Therefore there is a 
pressing need for the development of a cholera vaccine and there have been 
numerous research projects working towards this end for several decades. A 
few of them have been successful to date but because of the severe side 
effects and narrow range of protection, more effective and wider range 
vaccine development is still ongoing.  
In this study, crystallographic and enzymatic studies have been carried out on 
several novel proteins involved in the control of the production of the factors 
required for quorum sensing. Quorum sensing is a process in which bacterial 
cells communicate among themselves by the synthesis, release and detection 
of small chemical compounds called autoinducers. In this work, structural 
 xv	  
analysis was carried out on proteins involved in the synthesis and detection of 
the major autoinducer of Vibrio cholerae, named CAI-1. The crystal structure 
of CqsA involved in CAI-1 synthesis has been successfully solved and its 
enzymatic properties have been characterized. The structure of one domain 
of the cytoplasmic region of the CAI-1 receptor CqsS was also elucidated, and 
other domains were expressed. The crystal structure of another enzyme 
(VCA0859, an aldo-keto reductase) thought to have been involved in the 
synthesis of CAI-1 was also determined. Another protein named VCA0939 
was also studied, due to its importance in biofilm development, and its ability 
to control quorum-sensing in an alternative pathway in the mutated version of 
pathogenic strains of V. cholerae that were responsible for the seventh 
cholera pandemic. The aim of this project was to understand the three 
dimensional structure of some proteins that are involved in quorum sensing 
and control of the expression of virulence genes for the pathogenesis of V. 
cholerae. Understanding the three dimensional structure of the proteins and 
the mode of autoinducer binding to its specific receptor could be highly 
valuable in the development of a chemical compound that could lead to the 
discovery of a novel drug with the ability to target cross species specification.  
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1. Introduction 
1.1 Overview of Vibrio cholerae 
Vibrio cholerae is a dreadful human pathogen. It is the causative agent of 
cholera, an acute diarrhoeal infection characterised by profuse watery 
diarrhoea, vomiting, and abdominal cramp. Rapid loss of body fluid can lead 
to excessive dehydration and shock. Death can occur within a couple of 
hours, if untreated. Without medical treatment, mortality associated with 
cholera infection is 20-50 % (Sack et al., 2004).  
V. cholerae is a Gram negative curved rod shaped bacterium  that possesses  
a single polar flagellum  that gives it  a vibrating type of motility. The bacteria 
are also called ‘comma bacilli’ because of their characteristic curved shape 
(Figure 1.1). 
 
  
 
 
 
 
Figure 1.1 Characteristic curved rod shape of Vibrio cholerae (approximately 
× 10,000 Magnification) (Waldor and RayChaudhuri 2000) 
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1.2 Epidemiology 
In the Indian subcontinent, cholera has been an endemic disease for 
centuries. In 1563, a Portuguese physician, Garcia del Huerto, described 
cholera as an epidemic disease in Goa, India. In 1817, the first cholera 
pandemic spread outside the Indian subcontinent. It went towards the west as 
far as southern Russia. In 1826, the second pandemic started and reached 
the major European cities by the early 1830s.  
In 1883, Robert Koch successfully isolated the bacterium from the intestinal 
discharge of a cholera patient and proved that V. cholerae is the causative 
agent of cholera. There were three more pandemics, continuing up to 1925. 
These involved Africa, Australia, Europe, and all the Americas. Except for the 
Indian subcontinent, cholera did not persist in any of the new geographical 
areas that it had invaded (Sack et al., 2004). 
There are two major strains of V. cholerae, classical and El Tor and numerous 
other serogroups. The seventh pandemic was caused by the El Tor biotype 
and it involved almost the whole world. It began in Indonesia in 1905 and 
spread world wide in 1960. In 1964, it spread into India and then to Africa and 
Europe in 1970. In 1991, it invaded South America and caused recurrent 
epidemics in 1992 and 1993. This epidemic involved a total of 1,041,422 
cases with 9,642 deaths (0.9% of case fatality) from January 1991 to 
September 1994 in the Western Hemisphere (Cvjetanovic and Barua 1972; 
Baine et al., 1974; Goodgame and Greenough 1975; Kustner et al., 1981) 
(Figure 1.2).  
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Figure 1.2 The seventh cholera pandemic (Cvjetanovic and Barua 1972) 
Based on the heat stable ‘O’ antigen, V. cholerae, is currently classified into 
more than 200 ‘O’ serogroups. In 1992, there was an unusual cholera out- 
break in India and Bangladesh caused by a non-O1 serogroup of V. cholerae. 
It was then designated O139 Bengal (ICDDRB 1993). Initially, V. cholerae O1 
was considered as the causative agent of epidemic cholera, but after the 
recent epidemic outbreak due to non-O1 serogroup, O139 Bengal, it is 
assumed that these two serogroups now coexist and continue cholera 
outbreaks in India and Bangladesh. 
In Bangladesh, a cholera epidemic occurs twice a year corresponding to the 
warm seasons, before and after the rainy season (Siddique et al., 1992). In 
spring 2002, there was a cholera epidemic in Dhaka, Bangladesh caused by 
V. cholerae 0139 serotype that involved an estimated 30,000 cases (Faruque 
et al., 2003).  
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1.3 Recent cholera outbreak in Haiti  
The recent cholera outbreak is an ongoing cholera outbreak that resulted 
mainly as a consequence from a powerful earthquake that hit the country on 
12 January 2010. After the earthquake, there was no access to safe drinking 
water and people from the rural areas had to drink river water, resulting in the 
spread of the disease cholera in late October 2010 in Artibonite, a rural 
department of Haiti 100 kilometers (62 miles) north of the capital, Port-au-
Prince. About 4672 people were killed by cholera by March 2011 and 
thousands more were hospitalized. 
1.3.1 Source 
The suspected source for the epidemic was the Artibonite River, from which 
some of the affected people had drunk water. A UN team investigated 
samples of a suspected sewage spill from a Nepali peacekeeping base that 
may have infected the river system. Vincenzo Pugliese of United Nations 
Stabilization Mission in Haiti (MINUSTAH) confirmed that the tests were 
positive for cholera. The US CDC said its tests of "DNA fingerprinting" showed 
various samples of cholera from Haitian patients were identified as Vibrio 
cholerae serogroup O1, serotype Ogawa, a strain found in South Asia.  
1.3.2 Spread 
By March 2011, 252,640 cases had been reported. The disease had spread 
all over the country within a few months and also spread to neighboring 
countries, namely the Dominican Republic, United States and Venezuela. By 
May 21, 2011, some 5,200 deaths had been reported. The medical support 
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provided proved to be insufficient as more and more people were unable to 
receive treatment due to overcrowded hospitals. After Hurricane Tomas hit 
the island, there was an even greater fear of the disease spreading over the 
island as the result of flooding. 
The UN initially estimated that around 400,000 people would end up infected 
but later on the University of California has published a report that predicted 
that total infections would number up to 779,000 and total deaths up to 11,000 
by November 2011, nearly double the number estimated earlier by the UN. 
The revised numbers were based on more factors than the UN's estimates, 
which assumed a total infection rate of between two and four percent of the 
population In a statement released at the same time, the WHO said total 
deaths thus far had reached 4,672, with 252,640 cases reported (Andrews 
and Basu 2011) 
1.4 Cholera pathogenesis 
The life cycle of V. cholerae involves both environmental and human 
segments (Figure 1.3). The bacteria are usually transmitted by the faecal oral 
route via contaminated water or foods that contain live bacterial cells. The 
faeces of an infected person are usually the source of contamination. The 
diseases can spread further, if the area is not provided with adequate 
treatment of sewage and drinking water. After ingestion of contaminated food 
or water, the bacteria enter into the stomach, where most of the bacteria die 
because of stomach acids, and only a few that are embedded inside the 
biofilm can survive the acidic environment and manage to enter into small 
intestine to initiate colonization by the toxin co-regulated pilus (TCP). When 
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they manage to establish themselves in the small intestine of the host, they 
start secreting toxin. The cholera toxin (CT) is a potent enterotoxin. It consists 
of an A subunit and 5 smaller identical B subunits (Finkelstein and LoSpalluto 
1969). The B subunit serves to bind the toxin to the eukaryotic cell receptor. 
The A subunit possesses a specific enzymatic function that raises cAMP 
levels that lead to the net accumulation of excessive water and electrolytes 
into the lumen of the small intestine. The subsequent loss of fluid and 
electrolytes from the body leads to excessive dehydration and circulatory 
collapse associated with a severe form of cholera. The patient can die within a 
few hours, if the water and electrolytes are not replaced immediately. The only 
treatment so far available is the replacement of fluid and salt. Oral rehydration 
solution (ORS), a pre-packed mixture of sugar and salts isavailable in the 
markets and they need mixing with a certain amount of water and to be given 
to the diarrhea patients to drink in large amounts. But if the condition of the 
patient is very severe, they may need intravenous fluid replacement therapy. 
The resulting diarrhea associated with cholera also facilitates the bacteria to 
exit from one host into the environment and then again infect subsequent 
hosts. To maintain two distinct forms of life in the aquatic environment and in 
the human intestine, the bacteria requires the expression of a broad range of 
factors in a carefully controlled manner (Liu et al., 2006). 
Multiple environmental signals are known to control the gene expression in V. 
cholerae. In addition to the environmental signals, V. cholerae can also sense 
its own population density and respond accordingly to perform specific 
function such as biofilm formation and virulence gene expression. They 
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achieve this highly specified gene regulation by a process called quorum 
sensing. Quorum sensing is also exhibited by many Gram positive and Gram 
negative bacteria (Hammer and Bassler 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Life cycle of V. cholerae involves both environmental and human 
segments, which sometimes intersect (Sack et al., 2004) 
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1.5 Understanding Quorum sensing 
Bacterial cells need to communicate with each other within a single population 
in response to the changes in their population density and for the 
communication among different species, when sharing the same 
environmental niche. They may also need to communicate to eukaryotic hosts 
in order to live as parasites or living in a mutual relationship. Multi cellular 
organisms have the ability to secrete hormones to control and regulate 
function among different individual cells. Bacterial cells, unlike eukaryotic 
cells, lack the endocrine system to do so. Because they need to communicate 
within single species, and among different species, for their growth and 
survival, they have acquired their own unique way. They have the ability to 
synthesize and secrete chemical compounds, known as autoinducers, in 
response to the changing population density. Like the hormone receptors on 
the cell surface of multi cellular organisms, bacterial cell surfaces also have 
their own autoinducer specific cell surface receptors. These cell surface 
receptors vary with different bacterial species and their ligand (autoinducer) 
type. This type of communication established by synthesis, release and 
recognition within and among bacterial species is termed as quorum sensing 
(Henke and Bassler 2004a). 
In order to establish themselves in an environment, e.g. to establish a biofilm 
or perform specific function such as disease pathogenesis; a single bacterial 
cell is unable because it is too tiny in relation to the surrounding environment. 
The amount of chemicals released by a single bacterial cell, polysaccharide 
material or toxin will never be enough to establish itself inside the host cell for 
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disease development. But if the same function is carried out by millions of 
cells simultaneously, the concentration of the chemical released by them will 
be enough to perform the specific goal (Miller et al., 2002). So there is a need 
for the bacterial cells to switch on and off from one state to another to keep all 
of the individual cells in the same productive state within the population for 
infecting their host, or performing other functions such as bioluminescence or 
sporulation. 
Quorum sensing is the way of the bacterial cells to communicate among the 
population. When bacterial cells increase in number, the concentration of 
autoinducer they release also increase simultaneously. This increased 
amount of autoinducers will then be recognised and bound to their cognate 
receptors lying on the cell surfaces of the bacterial population. 
Binding of the autoinducers on their specific cell surface receptors then 
triggers a cascade of reactions that will ultimately end up with switching the 
bacterial cells to a different cellular state that will allow a specific function; for 
example, expression of some genes that were repressed previously. 
Autoinducers and their receptors vary with their function and producing 
organism. The quorum-sensing system in Gram-negative bacteria is different 
from that of the Gram-positive bacteria. 
The bioluminescent marine bacterium Vibrio fischeri is considered the 
paradigm for quorum sensing in most gram-negative bacteria (Hastings et al., 
1979). This group of bacteria usually involves the LuxI/R quorum sensing 
system (Engebrecht et al., 1983),(Fuqua et al., 1994). Two proteins, LuxI and 
LuxR, control expression of the luciferase operon (luxICDABE) required for 
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light production (Figure 1.4). 
 
 
 
 
 
 
 
Figure 1.4 Quorum sensing in Vibrio fischeri; a LuxI/R signaling circuit 
 Red triangles indicate the autoinducer that is produced by LuxI. OM, outer 
membrane; IM, inner membrane (Waters and Bassler 2005). 
LuxI is the enzyme called autoinducer synthase, which produces the acyl-
homoserine lactone (AHL) (Schaefer et al., 1996) and LuxR is the cytoplasmic 
autoinducer receptor/DNA binding transcriptional activator. The cells 
synthesize and release the AHL molecules outside the cells, which then and 
freely diffuse in and out of the cell and increases in concentration with 
increasing cell density. When the signal reaches a critical, threshold 
concentration, LuxR protein binds it and this complex activates transcription of 
the operon encoding luciferase (Waters and Bassler 2005). This  LuxR-AHL 
complex also induces expression of luxI because it is encoded in the 
luciferase operon. This results in the accumulation of numerous signaling 
molecules in the environment and creates a positive feedback loop that 
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causes the entire population to switch into “quorum-sensing mode” and 
produce light. Over 70 species of Gram-negative bacteria have been identified 
to employ the LuxI/R quorum sensing system (Fuqua et al., 2001; Miller and 
Bassler 2001). These systems are used for intra species communication 
because LuxR proteins and their cognate AHLs are extremely specific 
(Waters and Bassler 2005). 
Instead of AHL, Gram-positive bacteria use modified oligopeptides, usually 
ranging from 5 to 17 amino acids in length, as autoinducers. After translation 
as precursor peptides, they undergo some modification by the incorporation of 
lactone and thiolactone rings, lanthionines, and isoprenyl groups by the 
cellular machineries and are then secreted (Camilli and Bassler 2006). These 
autoinducers are then recognized by two-component signal transduction 
proteins called sensor histidine kinases. Upon binding of the autoinducer to its 
specific receptors, they trigger phosphorylation cascades that ultimately 
control regulation of quorum sensing target genes (Henke and Bassler 
2004a). 
Staphylococcus aureus is a classical example of a quorum sensing bacterium 
that is regulated by peptide molecules. This bacterium is considered as a 
normal skin micro flora but becomes a deadly pathogen when it penetrates 
into host tissues. These bacteria utilize a biphasic strategy to the 
pathogenesis of a disease: at low cell density, the bacteria express protein 
factors that promote attachment and colonization, but when they reach a high 
cell density, they start to express the proteins like toxins and proteases that 
are responsible for host cell damage.  
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This switch in gene expression programs is regulated by the Agr quorum-
sensing system (Figure 1.5). The system consists of an auto inducing peptide 
of Staphylococcus aureus (AIP) encoded by AgrD and a two-component 
sensor kinase-response regulator pair, AgrC and AgrA, respectively (Novick 
et al., 1995). The AgrB protein modifies S. aureus AIPs by adding the 
thiolactone ring. Upon binding of the AIP to its cognate sensor AgrC leads to 
phosphorylation of the protein AgrA. Resulting phospho-AgrA induces the 
expression of a regulatory RNA collectively known as RNAIII. Once RNAIII is 
expressed, it can repress the expression of cell adhesion factors and induce 
expression of secreted factors (Novick et al., 1993). 
Activated AgrA can also induce the expression of the agrBDCA gene cluster. 
The resulting level of increased AIP level ensures the entire population to be 
switched from the low-cell-density to the high-cell-density state (Novick et al., 
1995). 
 
 
 
 
 
Figure 1.5 two-component response regulatory systems in St. aureus 
Small red circles indicate the AIP. P2 and P3 designate the promoters for 
agrBDCA and RNAIII, respectively (Waters and Bassler 2005). 
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Figure 1.6 Representative bacterial autoinducers 
 The asterisk above the tryptophan in ComX represents an isoprenyl 
modification (Waters and Bassler 2005). 
There is another quorum sensing system, which is a hybrid between the 
Gram-negative and Gram-positive bacteria (Henke and Bassler 2004a). This 
hybrid system, first identified in bioluminescent marine bacterium Vibrio 
harveyi, employs two autoinducers, AI-1 and AI-2 (Bassler et al., 1993). AI-1 
is an AHL as found in Gram-negative bacteria and AI-2 is a furanosyl borate 
diester.  
AI-1 and AI-2, upon binding to their cognate sensors, trigger a signal 
transduction cascade by a two component phosphorylation kinase similar to 
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that in Gram-positive bacteria(Henke and Bassler 2004a) (Figure-1.7). 
 
 
 
 
 
Figure 1.7 Three general classes of quorum-sensing systems (Henke and 
Bassler 2004a) 
1.6 Understanding V. cholerae quorum sensing 
A number of studies have been carried out to investigate the regulation of 
virulence gene expression in V. cholerae. These studies have identified a 
number of genes that are responsible for the virulence factor production in V. 
cholerae, and are controlled by quorum sensing. These studies also reveal 
that termination of virulence and the self limiting nature of cholera bacteria are 
also controlled by quorum sensing (Higgins et al., 2007). 
During life in the aquatic environment, the bacteria live in association with 
various phytoplanktons and zooplanktons (Islam et al., 1990). They can also 
live in the form of biofilms. Biofilms are specialized structures that are 
composed of bacterial self produced extracellular polymeric substances in 
which bacterial cells are embedded. This specialized structure not only helps 
the bacteria to survive on biotic and abiotic surfaces, but also helps in 
initializing human infection. When bacteria are within the biofilm, these 
 16	  
structures help the bacteria to be concentrated up to millions of cells to initiate 
a symptomatic disease (Colwell et al., 2003). Because bacterial biofilms are 
1,000 fold more resistant to acidic shock, it is also possible that the biofilm 
facilitates the bacterial survival through the acidic condition of the stomach 
(Liu et al., 2006). 
After entering into the host intestine, the bacteria establish themselves in the 
host gut environment. They must penetrate the mucous layer and adhere to 
the intestinal epithelial cells to colonize there. The bacteria produce their 
virulence factors such as cholera toxin (CT) and toxin co-regulated pilus 
(TCP) to establish themselves in the gut environment. TCP is a type IV pilus 
encoded by a gene in the vibrio pathogenicity island (VPI) and its function is 
to mediate adherence to the intestinal mucosal cells. Once the bacterium is 
established in the gut environment, it is able to multiply extensively and 
produce cholera toxin. CT is mainly responsible for the characteristic watery 
diarrhea associated with cholera (Kaper et al., 1995). The genes responsible 
for the production of cholera toxin, ctxA and ctxB are not located in the 
bacterial chromosomal genome but they are part of a bacteriophage genome 
called CTXφ (Waldor and Mekalanos 1996). In addition to the TCP and CT, V. 
cholerae also produces a number of proteins such as hemagglutinin and 
accessory colonization factor for non-fimbrial adhesion and for tighter binding 
with the host cells (Peterson and Mekalanos 1988). 
Previous studies have identified that a number of genes encoding virulence 
factors of V. cholerae such as CT, TCP and other genes responsible for 
biofilm formation are regulated by quorum sensing. In addition, protease 
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production, chemotaxis, motility and some other phenotypes are regulated by 
quorum sensing in these bacteria (Liu et al., 2006). 
Like V. harveyi, V. cholerae uses two parallel quorum sensing systems, CAI-1 
(cholera autoinducer 1, Figure 1.9) and AI-2 (autoinducer 2). CAI-1 is an S-3-
hydroxytridecan-4-one and AI-2 is a furanosyl borate diester produced by the 
enzymes CqsA and LuxS, respectively (Higgins et al., 2007). AI-2 is also 
produced by V. harveyi and many other Gram negative and Gram-positive 
bacteria. AI-2 is thus believed to function in interspecies communication 
(Waters and Bassler 2005).  CAI-1 is produced only by V. cholerae and V. 
harveyi and is believed to function in species-specific communication. These 
autoinducers help the bacteria to respond to density specific behavior. Once 
produced, CAI-1 and AI-2 diffuse across the cell membrane and bind to the 
cell surface receptors CqsS and LuxPQ respectively. In both of the cases, 
autoinducers binding to their cognate receptors, trigger the receptors to 
change from functioning as kinases to phosphatases (Higgins et al., 2007), 
(Camara et al., 2002) 
During the early stages of cholera infection, at low cell density CqsS and 
LuxQ act as kinases and phosphorylate LuxO protein. Phosphorylated LuxO 
activates the transcription of genes called Qrr1– 4 (quorum regulatory RNAs). 
The Qrr sRNAs, and a molecular chaperone Hfq then block the expression of 
quorum sensing regulatory protein HapR. Now HapR-repressed genes, genes 
for biofilm formation and virulence factor production are expressed to continue 
the disease process. In this state, HapR-activated genes are not expressed 
(Hammer and Bassler 2007) (Figure 1.8). 
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Figure 1.8 The Vibrio cholerae QS circuit 
HapR-dependent (A) and HapR -independent (B) pathways are controlled by 
Qrr sRNAs and Hfq (Hammer and Bassler 2007). 
After several rounds of multiplication through the disease process, the 
bacterial cell population is able to develop biofilm, produce cholera toxin and 
other virulence factors to make clinical disease. At this high cell density state, 
binding of CAI-1 to CqsS and AI-2 to LuxPQ causes de-phosphorylation and 
inactivation of LuxO protein (Hammer and Bassler 2007). De-phosphorylated 
LuxO cannot activate the transcription of genes of quorum regulatory RNAs, 
thus allowing the HapR to accumulate and control gene expression (De Silva 
et al., 2007). V. cholerae virulence genes are then shut down and the bacteria 
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are released from the host gut into the environment in large numbers. They 
can now initiate another round of the infectious cycle. 
In high cell density, quorum sensing not only terminates the virulence gene 
expression in V. cholerae, but also inhibits its biofilm formation. This is also an 
interesting character of this bacterium because other bacteria use quorum 
sensing to develop their biofilm at high cell density (Hammer and Bassler 
2007). The process of development of biofilm requires multiple steps and is 
controlled by a number of interacting regulatory pathways (Watnick and Kolter 
1999). The process starts when a bacterium approaches to the host cell 
surface. It then reduces its motility and forms an association with the surface. 
The bacteria then begin to multiply and secrete exopolysaccharide around 
their surface and form a micro colony. In the micro colony, continual bacterial 
growth and secretion of exopolysaccharide then develop a mature biofilm with 
pillars and channels. The whole process of biofilm development is dependent 
on the production of exopolysaccharide. V. cholerae exopolysaccharide is 
called VPS and VPS synthesis requires the function of 17 proteins that are 
encoded by two linked operons: vpsA-K and vpsL-Q, located on the V. 
cholerae large chromosome (Yildiz and Schoolnik 1999). 
V. cholerae biofilm formation is tightly regulated to help the bacterial 
adaptation in different environments during stages in its life cycle. A number 
of intracellular and environmental regulators have been identified that are 
required for vps gene expression (Casper-Lindley and Yildiz 2004). Among 
the intracellular regulators, VpsR and VpsT have been found to positively 
regulate vps gene expression (Chapter-6). In addition, intracellular 
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concentration of cyclic diguanylate (c-diGMP) can also regulate vps gene 
expression. Intracellular concentration of (c-diGMP) is negatively controlled by 
GGDEF domain containing proteins that function as diguanylate cyclase and 
EAL domain containing proteins that function as phospho diesterases. V. 
cholerae has been found to contain 53 genes, encoding either or both of the 
domains. Some of these enzymes have been found to regulate biofilm 
development either positively or negatively (Lim et al., 2006). 
To determine the possible role of autoinducers in the regulation of biofilm 
development, some experiments have been done (Hammer and Bassler 
2003). In the cqsA mutant and luxS mutant strain of V. cholerae, vps gene 
expression was proven with the development of the biofilm. The luxS mutant 
strain produced normal biofilm but the biofilm produced by the cqsA mutant 
was thicker than the normal one. This indicates that in the cqsA mutant strain, 
the expression of the vps gene was elevated. Addition of exogenous CAI-1 in 
the cqsA mutant culture resulted in normal biofilm development. This result 
proved that CAI-1 is able to control the biofilm development in V. cholerae. 
In V. cholerae, autoinducers promote termination of the virulent stage of the 
bacteria rather than inducing its virulence. Triggering quorum sensing by an 
autoinducer is a potential strategy for therapeutic intervention in the 
pathogenesis of this bacterium. 
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1.7 Aim of my Study 
The main objective of my study is to carry out a structural study of some 
proteins involved in quorum sensing in V. cholerae. An understanding of these 
proteins may provide information for the development of new drugs. Although 
there are some anti-diarrheal drugs available in the market, they are not 
effective in cholera treatment. Antibiotics can shorten the disease course and 
diminish the severity of illness, but still dehydration causes most of the 
patients’ sufferings (Casburn-Jones and Farthing 2004). No vaccine has yet 
been proven to be ideal for the disease. Vaccines that are currently available 
are not licensed yet to be used as an infection control tool and can provide 
protection against only limited strains of pathogenic V. cholerae. Although it 
can provide specific protection against V. cholerae serotype O1, it cannot 
provide protection against other non-O1 serotype strains. The only vaccine 
licensed in the UK is called  “Dukoral” which is prepared according to British 
National Formulary and is prepared by inactivation of four strains of V. 
cholerae O1 serotypes in combination with non-toxic version of cholera toxin 
B-subunit (prepared from genetically modified bacteria). Additionally, the 
range of protection is dependent on the route of administration. For example, 
an oral dose of the toxin induces the production of secretory IgA locally on the 
epithelial cells lining the intestine. This can cause several side effects 
including diarrhoea like symptoms, nausea and vomiting or abdominal cramp. 
The symptoms can occasionally be very serious and may cause rash, 
arthralgia (joint pain), par aesthesia (number of abnormal sensations in the 
body and a variety of neuropathic pains) and flu-like syndrome.  
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Alternatively, administration of a parenteral formulation (which consists of 
attenuated live pathogenic bacteria) can provide protection for three to six 
months but the efficacy is only 50% and occasionally causes several severe 
adverse reactions. Because of its adverse effects and limited protection, 
parenteral vaccine is not recommended anymore in the UK (National Library 
for Health). 
Unlike many other bacterial species, in which quorum sensing induces 
virulence, in the case of V. cholera, the process terminates virulence. So there 
is a possibility that, if we can trigger the quorum-sensing pathway of the 
bacteria, by providing a synthetic autoinducer, the process can be used 
therapeutically. CAI-1 has been proven to be the major autoinducer for 
triggering quorum sensing pathway in V. cholera (Figure-1.9) (Higgins et al., 
2007). 
 
 
 
 
 
 
Figure 1.9 Simplified model for quorum sensing in V. cholerae (Higgins et al., 
2007) 
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The main purpose of my study was to understand the detailed three-
dimensional structures of CqsA, the enzyme that makes the CAI-1, and the 
CAI-1 receptor protein CqsS. It is hoped that understanding the three 
dimensional structure of receptor-ligand binding will greatly aid the designing 
of a synthetic molecule that will be able to trigger the quorum sensing 
pathway in an efficient way without going through the disease process. To use 
a molecule as a drug, the molecule must be specific, stable and easily 
deliverable to the infection site. There are some public health related issues 
also: activation of quorum sensing can induce active movement of the 
bacteria and can enhance the spread of bacteria from one host to another 
(Parsek 2007). Later on, two more proteins, aldo-keto reductase of V. 
cholerae (VCA0859) and a GGDEF domain containing protein that functions 
as diguanylate cyclase (VCA0939) were also included in the project. Because 
aldo-keto reductase can reduce an aldehyde group or a keto group, it was 
believed to be involved in the catalytic pathway following CqsA to synthesize 
the final product CAI-1. VCA0939 was incorporated in the project because of 
its importance in quorum sensing for biofilm formation and there has been no 
report of crystal structure of this important protein so far. Detailed structural 
information for the proteins involved in this pathway would be very valuable in 
advancing studies in this area. 
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Chapter 2 
Structural determination of CqsA 
 
 
 
 
 
 
 25	  
2. Structural determination of CqsA 
2.1 Overview of CqsA  
CqsA is the enzyme that synthesizes CAI-1, the major autoinducer of V. 
cholerae (Higgins et al., 2007). It is a pyridoxal phosphate (PLP) dependent 
amino transferase enzyme that contains 389 amino acid residues. The 
molecular weight of this protein is 43,594 Da and its calculated isoelectric 
point (pI) is 6.23.  
From bioinformatics analysis CqsA was predicted to be a member of the 
enzyme group named α-oxo amine synthases (AOS). This family of enzymes 
catalyses the condensation of a specific amino acid with an acyl-CoA 
thioester substrate in a PLP dependent manner. A number of members have 
been characterised structurally and functionally from this family to date that 
have some common conserved residues in their active site that determines 
the choice of amino substrate to be used by that particular enzyme (Figure 
2.2). (Alexeev et al., 1998),(Astner et al., 2005),(Schmidt et al., 2001), (Yard 
et al., 2007). All of the members with a known structure and function show a 
common pathway of catalysis and a conserved lysine residue that can form a 
Schiff-base with PLP (Lys236 in CqsA and Lys258 in LqsA, a homologue of 
CqsA from the pathogen Legionella pneumophilia) (Spirig et al., 2008),(Eliot 
and Kirsch 2004). All the structures of this family solved to date show a 
dimeric form where the PLP binding site is highly conserved. 
Family members of this enzyme group generally follow a common mechanism 
of catalysis that involves several steps: First, formation of an external aldimine 
with the incoming amino acid substrate that displaces an internal lysine-PLP 
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aldimine. Then formation of a quinonoid intermediate through abstraction of 
the α-proton from the external aldimine. Then condensation with the acyl-CoA 
substrate followed by displacement of the CoA to form a β-keto acid, which is 
followed by the decarboxylation to form a quinonoid. Then protonation of the 
quinonoid to form the product external aldimine, and finally release of the α-
oxo amine product and regeneration of the internal PLP-aldimine (Zaman et 
al., 1973; Hayashi 1995; Webster et al., 2000; Kerbarh et al., 2006; Yard et 
al., 2007). Sequence and structural similarity of CqsA to the AOS family and 
the chemical structure of CAI-1 suggested that CqsA may catalyse the first 
step in its biosynthesis through condensation of an amino acid, either L-2-
aminobutyric acid (Figure 2.1, 2a) or L-threonine (Figure 2.1, 2b), with 
decanoyl-CoA (Figure 2.1, 3) to give products (Figure 2.1, 4a or 4b). To better 
understand the role of CqsA in the formation of CAI-1, the cqsA gene was 
overexpressed in E. coli, crystals of CqsA were obtained for structural studies. 
This chapter focuses on the structure determination of CqsA and its complex 
with the cofactor PLP. The binary and ternary complexes will be discussed in 
Chapter 3. 
 
 
 
Figure 2.1 Synthesis of CAI-1 (1) 
 Potential substrates (2,3), and possible products of the reaction catalysed by 
CqsA. 
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2.2 Multiple sequence alignment and conserved amino acids 
 
 
 
 
 
 
 
 
 
Figure 2.2 Sequence alignment of V. cholerae CqsA with members of the 
AOS family 
8-amino-7-oxononanoate synthase (AONS), 2-amino-3-ketobutyrate-CoA 
ligase (KBL), and serine palmitoyltransferase (SPT), 5-aminolevulinate 
synthase (ALAS) and the autoinducer synthase from the Paris strain of 
Legionella pneumophila (LqsA). The secondary structure (coil for α-helix and 
arrow for β-strand) of AONS is shown above the sequences and that of CqsA 
is shown below. Residues involved in PLP binding are indicated by ‘PLP’; 
those forming the hydrophobic pocket accommodating the acyl chain are 
shown by an asterisk. This figure and all the sequence alignments were 
produced using ClustalW2 (Larkin et al., 2007) and ESPript (Gouet et al., 
2003). 
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2.3 Cloning, protein expression and purification  
2.3.1 Cloning 
The cqsA gene (locus vca0523) was amplified by polymerase chain reaction 
(PCR) from genomic DNA of V. cholerae O1 El Tor strain N16961 (kindly 
provided by Dr. E. Fidelma Boyd) using standard protocols (Appendix I-5) 
(Figure 2.3.A). Forward (AGGATATATTGCCATGGACAAGCCTC) and 
reverse (GCAGTTTTTGTTGTCGACGCATTTAAC) primers were designed 
corresponding to the 5ʹ′ and 3ʹ′ ends of cqsA with specific recognition sites for 
the restriction enzymes NcoI and SalI. After amplification, the PCR products 
were digested with NcoI and SalI enzymes and cloned into the similarly 
digested pLOU3 vector (an engineered vector derived from the NEB vector 
pMAL-c2x that allows cytoplasmic expression with a six histidine tag, the 
maltose-binding protein (MBP), and tobacco etch virus (TEV) protease 
cleavage peptide fused to the N-terminus). The ligation products were then 
transformed into the cloning host TamI E. coli cells. The transformed cells 
were plated on LB agar containing ampicillin and incubated at 37 °C 
overnight. Colonies containing recombinant vector DNA were identified using 
colony PCR screening (Figure 2.3.B). The presence of correct cqsA gene was 
confirmed by sequencing (Section I-11). 
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Figure 2.3 Agarose gel electrophoresis of cqsA gene cloned into pLOU3 
Plasmid (A) PCR and (B) colony PCR product 
2.3.2 Protein expression and optimization of solubility 
The pLOU3 vector containing the cqsA gene was transformed into 
Escherichia coli strain BL21 (DE3) and Rosetta (DE3) cells. In order to 
achieve soluble expression of the proteins, the cells were grown at 37 °C at a 
volume of 10 ml up to an optical density value of 0.5 at λ = 600nm. Then the 
cells were subjected to induction with IPTG (isopropyl-beta-D-
thiogalactopyranoside) at a concentration of 1mM. Following induction, the 
cells were grown for three hours at 37 °C. Soluble expression of CqsA was 
obtained successfully. 
2.3.3 Protein purification 
The expression trial was then scaled up for five litres of culture and purified 
using the standard method described later (Section III-2.1) using purification 
buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 10-350 mM Imidazole). Soluble 
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CqsA protein was purified by nickel column purification, histidine tag cleavage 
and gel filtration chromatography following the standard protocols as 
described later (Section III-2.1, Figure 2.4).  The molecular weight of the 
protein CqsA with MBP plus histidine tag is 88.5 kDa and without tag is 43.5 
kDa. Protein purity was analyzed by SDS PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) and the correct identity confirmed by 
Mass Spectrometry (Section III-1, Figure 2.4. G). The protein samples were 
concentrated to 8 mg/ml using a 10,000-Da MWCO centrifugal concentrator 
(Milipore). Two ml of pure protein was obtained, small aliquots of 50 µl of the 
protein sample were flash frozen in liquid nitrogen and stored at -80 °C. The 
PCT™ (Pre-Crystallization Test from Hampton Research) was used to 
determine the appropriate protein concentration for crystallization screening 
(section IV-1).  
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Figure 2.4 Purification of CqsA protein 
 (A) First Ni2+-affinity column purification. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4-5, column wash with the buffer containing 10 mM 
imidazole; lane 6-9, elution in buffer containing 350 mM imidazole. (B) TEV 
cleavage of MBP-tagged CqsA. Lane 2-3, TEV digested sample of CqsA. (C) 
Second Ni2+-affinity column. Lane 1, TEV digested sample, pre column; Lane 
4-5, CqsA without MBP. (D) Gel filtration chromatogram for CqsA protein. (E) 
Eluted CqsA protein after gel filtration chromatography. (F) Eluted CqsA 
protein after Anion-exchange chromatography (Ion chromatogram not shown). 
(G) Matched peptides of CqsA identified by mass spectrometry. 	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2.4 Protein crystallization and X-ray data collection 
A Pre-crystallization test (Section IV-1) indicated the appropriate protein 
concentration (8 mg/ml) for crystallization screening. Four crystal screens 
(Classics, PEGs, ANIONS and JCSG) were used in initial crystallization trials 
of native CqsA. This experiment was carried out using the sitting drop 
diffusion method (Section IV-2). A beautiful crystal was observed after one 
week (Figure 2.5. A) in JCSG - C11. The condition was 0.1 M Bis-Tris, pH 5.5 
and 2 M ammonium sulphate.  
2.4.1 Crystal optimization  
The initial hit was optimized by varying the pH and the concentration of salt, 
precipitant and protein. The best quality crystals were obtained in an 
optimization condition of 0.1 M Bis-Tris pH 5.5 and 1.5 M ammonium 
sulphate. The crystal was about 500 µm in length x 200 µm in diameter and 
about 200 µm in thickness (Figure 2.5. B) 
The crystal was picked out from the drops with a crystal loop (0.2-0.5 mm 
size) and transferred to 5 µl of cryo-protectant drop (with 10% glycerol and 
10% ethylene glycol). The crystal was then re-looped and diffraction data 
were collected at 100K on the in-house Rigaku/MSC MicroMax-007HF 
rotating anode equipped with a Saturn 944+ CCD detector at a wavelength of 
1.54178 Å. The crystal-to-detector distance, rotation angle and other 
parameters were initially set to measure a 2.7 Å resolution data set for 
preliminary analysis (Figure 2.5. C). For further comprehensive data 
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collection, the detector was set at different distances based on the diffraction 
quality of the crystal. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Crystal and diffraction pattern of CqsA  
(A) Native, (B) PLP soaked Crystals of CqsA and (C) X-ray image of CqsA 
crystal. 
To get the PLP bound in the active site of the enzyme, different strategies 
were taken separately and together, for example excess PLP was added in 
the purification buffer and the purified enzyme was also dialyzed in the 
presence of excess PLP (50 µM to 5mM). The crystallization buffer also 
contained excess PLP. But unfortunately, the PLP bound yellow enzyme 
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could not be crystallized. Soaking the crystal in the presence of 5mM PLP 
helped to get a structure at 2.1 Å (Table 2.1) that has a PLP at least sitting in 
the active site. But the PLP is not covalently bound to the active site lysine 
236 residue. The binary complex of CqsA with PLP and threonine was 
obtained by soaking the crystal in lithium sulphate buffer containing 5 mM 
PLP + 5 mM threonine. The ternary complex of CqsA with PLP, threonine and 
decanoyl-CoA was obtained by soaking the crystal in lithium sulphate buffer 
containing 5 mM PLP + 5 mM threonine + 5 mM decanoyl-CoA (Table 2.1).?
2.4.2 X-ray data processing, structure solution and refinement 
The data was indexed, integrated and scaled in DENZO program HKL2000 
(Minor 1997). Analysis of the solvent content suggested that there were two 
molecules in the asymmetric unit (50% solvent; Matthew’s co-efficient 2.25 
Å3/Da). However, an initial attempt to solve the structure by molecular 
replacement using of KBL (PDB code 1FC4) was not successful and it was 
necessary to use an ensemble of four different superimposed models in 
PHASER: 356 Cα atoms of KBL (24% identity) superimpose with an rmsd of 
1.9 Å; 328 Cα atoms of AONS (27% identity) superimpose with an rmsd of 1.9 
Å; 340 Cα atoms of ALAS (27% identity) superimpose with an rmsd of 2.0 Å, 
and 341 Cα atoms of SPT (25% identity) superimpose with an rmsd of 2.2 Å. 
This latter molecular replacement step and partial refinement of the structure 
was performed by Dr Jane Potter.  
X-ray data for the apo (without PLP) and holo (with PLP) forms of the CqsA 
were collected in house. Data for the PLP + threonine + decanoyl-CoA were 
collected at ESRF. Details of the data sets are in Table 2.1.
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Table 2.1 X-ray data collection and refinement statistics 
 
Rmerge = ∑hkl ∑i |Ihkl, i – 〈 Ihkl 〉| / ∑hkl 〈 Ihkl 〉  Rcryst and Rfree = (Σ | |Fo| - |Fc| |)/(Σ 
|Fo|). Numbers in parentheses correspond to the highest resolution shell. 
2.5 Overall structure of CqsA 
The asymmetric unit of the CqsA crystal contains a dimer. Each monomer 
contains 389 amino acids. In the apo structure, no clear electron density was 
Data set Apo Holo (PLP) PLP + L-
threonine 
PLP + L-
threonine + 
decanoyl-CoA 
A. Data collection     
Resolution (Å) 177.0 – 2.50 
(2.53 – 2.50) 
28.0 – 2.10 
(2.14 – 2.10) 
89.0 - 1.90 
(1.97 - 1.90) 
20.0 - 1.91  
(2.01 - 1.91) 
Space group 
P21212 
Unit cell (Å) 
a 
b 
c 
 
177.3 
70.1 
70.7 
 
177.3 
70.1 
70.6 
 
177.3 
70.0 
70.7 
 
178.0 
70.4 
70.6 
X-ray source in-house in-house ESRF ID14-1 ESRF ID14-1 
Wavelength (Å) 1.542 1.542 0.934 0.934 
No. of unique 
reflections 
28,035 50,632 67,680 63,292 
Completeness (%) 94.2 (88.2) 96.5 (96.0) 99.0 (98.9) 91.2 (83.3) 
Redundancy 2.9 (2.2) 5.1 (4.3) 5.1 (4.8) 5.7 (4.7) 
Rmerge 0.074 
(0.550) 
0.080 (0.545) 0.048 (0.397) 0.052 (0.467) 
I/σI 25.0 (3.0) 15.3 (2.2) 24.9 (3.5) 22.3 (3.5) 
B. Data 
refinement 
    
Number of atoms 
Protein 
Ligand 
 
 
Water 
 
6039 
10 (2 SO4) 
 
 
0 
 
6039 
57 (2 PLP, 5 
SO4) 
 
762 
 
6039 
61 (PLP, 
external 
aldimine, 5 SO4) 
643 
 
6039 
67 (2 external 
aldimines, 2 
SO4, 1 Cl-) 
824 
Average B-factor 
(Å2) 
Protein, chain A/B 
Ligand 
Water 
 
44 / 40 
30 
- 
 
40 / 33 
25 
43 
 
36 / 31 
25 
41 
 
28  / 24 
22  
42 
Rcryst 
Rfree 
0.206 
0.286 
0.197  
0.258 
0.199 
0.240 
0.200 
0.253 
rmsd from ideal 
Bond lengths (Å) 
Bond angles (º) 
 
0.007 
1.120 
 
0.008 
1.211 
 
0.005 
0.916 
 
0.007 
1.176 
PDB code 2wk7 2wk8 2wk9 2wka 
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observed for residues 21-43 and 68-89 and were predicted to be disordered. 
In the PLP complex holo enzyme structure, some of the residues become 
more ordered. The structure of all AOS member proteins contains three 
domains in common: an N-terminal domain (residues 1-56, dark blue in 
(Figure 2.6), a central catalytic domain (residues 57-286) and a C-terminal 
domain (residues 287-389). All three of them are involved in dimer formation. 
The distribution of the secondary structural elements is very similar to that of 
other AOS members (Figure 2.2). Structural alignment of CqsA with its 
homologous proteins reveals that CqsA is structurally very similar to other 
AOS members. 
 
 
 
 
 
Figure 2.6 CqsA apo-enzyme structure 
 Schematic drawing viewed along the dimer axis. Each monomer is drawn in 
rainbow colours from blue at the N-terminus to red at the C-terminus. The 
three domains of each monomer are defined as the N-terminal helix (deep 
blue), the central catalytic domain and the C-terminal domain (encompassing 
the orange and red structural elements on the edges of this figure). This figure 
and all the protein structures were prepared using Pymol (DeLano, 2007). 
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2.5.1 PLP-binding pocket 
Although it was not possible to obtain a Schiff-base complex of PLP with 
CqsA, (internal aldimine) which is supposed to be formed between PLP and 
the conserved lysine, Lys236 in CqsA, a holo CqsA structure was obtained by 
soaking the apo crystals in the presence of 5 mM PLP. The reason for no 
bond formation between Lys-PLP may have been due to the presence of 1.5 
M of ammonium sulphate in the crystallization solution. The interactions 
between PLP and the enzyme are very similar to those seen in other AOS 
members (Figure 2.2 and 2.7).  
 
 
 
 
 
 
Figure 2.7 CqsA holo-enzyme structure 
Each monomer is drawn in rainbow colours from blue at the N-terminus 
(identified by a blue sphere at residue 4) to red at the C-terminus (identified by 
a red sphere at residue 389). The three domains of each monomer are 
defined as the N-terminal helix (deep blue), the central catalytic domain and 
the C-terminal domain (encompassing the orange and red structural elements 
on the edges of this figure). The PLP present in each active site is drawn in 
space filling mode.  
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The phosphate oxygen interacts with main chain amide groups of Gly108, 
Trp109, Ser266 (of the other monomer), and the Oγ atoms of Ser233 and 
Ser265 (of the other monomer), residues that are Ser or Thr in other AOS 
members (Figure 2.2 and 2.8). The pyridinium atom of PLP (N1) interacts with 
Asp202, a residue conserved in the AOS family that has been suggested to 
stabilize a protonated pyridinium form of PLP (Hunter and Ferreira 1999). The 
PLP O3 interacts with the side chain of conserved His205, and the ring of PLP 
stacks onto conserved His133. The O4A atom of PLP is 2.8 Å from the Nε of 
Lys236, the conserved lysine that forms an internal aldimine with PLP.  
 
 
 
 
 
Figure 2.8 Stereo images of the PLP binding site 
Stereo drawing with a sigma-a Fo-Fc map contoured at 3σ. Monomer A is 
coloured green and monomer B is coloured cyan, with water molecules shown 
as red spheres. Hydrogen bonds in this and other figures are indicated by 
dotted lines connecting atoms ≤ 3.2 Å apart 
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Functional analysis of CqsA 
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3. Functional analysis of CqsA 
3.1 UV spectroscopy of external aldimine formation 
Initial assay of the CqsA was carried out using uv-2101PC (SHIMADZU). The 
protein sample was scanned over the range of 300 nm to 480 nm 
wavelengths with the addition of PLP ranging from 10 µM up to 70 µM. An 
increase of absorbance of the protein spectra was observed around 334 and 
425 nm wavelengths. After 80 µM of PLP, molar ratio of 1:1, no further 
increase of absorbance was observed. The binding affinity of CqsA and PLP 
was found to be at a molar ratio of 1:1. The amino transferase assay was 
carried out in a volume of 1ml containing 80 µM of enzyme in 20mM HEPES 
(pH 7.5), 200mM NaCl. 80 µM of PLP and five different amino acids: 
threonine, serine, glycine, alanine and L-2-aminobutyric acid in the same 
molar concentrations (5 mM). Corresponding standards were also used 
contained all other components except CqsA. Decanoyl-CoA (50-500 µM) 
(SIGMA) was also included in some assays. After addition of the substrate, 
the reactants were mixed well and incubated at 30 °C for 30 minutes. Then 
the absorbance of the reaction mixtures were taken and recorded against 
their corresponding standard (Webster et al., 2000). The absorbance 
spectrum of CqsA exhibits peaks at 334 and 425 nm (Figure 3.1.A and 3.1.B), 
characteristic of the non-coplanar and coplanar forms of a CqsA-PLP internal 
aldimine complex (Webster et al., 2000; Yard et al., 2007). An increase in 
absorbance at 425 nm was observed with L-threonine and L-2-aminobutyric 
acid (Figure 3.1.A and 3.1.B), as described for other AOS family members 
upon formation of an external aldimine with an amino acid, suggesting the 
formation of an external aldimine.  
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Figure 3.1.A Assay with threonine 
 
 
 
 
 
 
Figure 3.1.B Assay with L-2-amino butyric acid 
In search of the fatty acyl substrate, decanoyl-CoA was used with both the L-
threonine and the L-2-amino butyric acid. The absorbance was shown to 
further increase in case of threonine (figure not shown) but not in case of L-2-
amino butyric acid. It was also possible to trap an aliphatic reaction 
intermediate (10-carbon acyl chain of decanoyl-CoA) when CqsA crystals 
were soaked along with L-threonine. No such result was found with L-2-amino 
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butyric acid because it destroys the diffraction of the crystal. Another assay 
was performed in a Cary-50 UV-Vis (VARIAN) using L-2-amino butyric acid 
and with L-2-amino butyric acid and decanoyl-CoA (Kelly et al., 2009) (Figure 
3.1.C, Figure 3.1.D). 
 
Figure 3.1.C Assay with L-2-amino butyric acid 
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Figure 3.1.D Assay with L-2-amino butyric acid and decanoyl-CoA 
3.2 Crystal soaking experiment 
Soaking the crystal in the presence of 5mM PLP helped to get a structure at 
2.1 Å (Table 2.1) that has a PLP at least sitting in the active site. But the PLP 
is not covalently bound to the active site lysine 236 residue. Again, soaking 
the crystal in lithium sulphate buffer containing 5 mM PLP + 5 mM threonine 
and 5 mM PLP + 5 mM threonine + 5 mM decanoyl-CoA helped to get some 
more electron density that was useful to build the missing portion of the 
chains (Figure 3.2.A, Figure 3.2.B) (Table 2.1). 
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Figure 3.2.A CqsA enzyme structure with trapped external aldimine 
 
Figure 3.2.B Location of the 69-86 loop in active site of CqsA 
The secondary structure of the loop is coloured red. Decanoyl-CoA substrate 
is likely to enter via the entrance to the right. 
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3.2.1 Trapped external aldimine  
Binary complex 
 
The crystals soaked in 5 mM PLP and 5 mM threonine in LiSO4 buffer 
diffracted at 1.9 Å (Figure 3.2.C, Table 2.1). The difference electron density 
clearly shows a trapped external aldimine binary complex. Although the side 
chain of threonine is missing, overall interactions of the external binary 
complex with the active site residues are similar to its homologous enzymes 
(Figure 2.2 and 3.2.C). 
 
 
 
 
 
Figure 3.2.C Stereo images of the trapped external aldimines 
Complex formed with PLP and L-threonine, monomer A is coloured green, 
monomer B is coloured cyan, and a sigma-a weighted Fo-Fc map is 
contoured at 2.5σ. 
Ternary complex 
The crystals soaked in 5 mM PLP and 5 mM threonine and 5 mM decanoyl-
CoA in LiSO4 buffer also diffracted at 1.9 Å (Figure 3.2.D, Table 2.1). A 
positive density became visible that could accommodate a whole ternary 
complex formed by PLP, threonine and decanoyl-CoA. Although it was not 
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possible to trace the CoA molecule in the structure as was found in the 
structure of ALAS with succinyl-CoA (Astner et al., 2005). The 10-carbon acyl 
chain of decanoyl-CoA sits in an enclosed hydrophobic pocket lined by His30, 
Val32, Phe79, Phe257*, Ile263*, Phe264*, Cys346, Pro348 and Ala349, 
where the asterisk denotes the other monomer. The keto group of the acyl 
chain interacts with the Ne2 of conserved His133 that stacks with PLP.  
 
 
 
 
 
Figure 3.2.D Stereo images of the trapped external aldimines  
Complex formed with PLP, L-threonine and decanoyl-CoA, monomer A is 
coloured green, monomer B is coloured cyan, and a sigma-a weighted Fo-Fc 
map is contoured at 2.5σ. 
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Figure 3.2.E CqsA enzyme structure with trapped external aldimine 
Each monomer is drawn in rainbow colours from blue at the N-terminus 
(identified by a blue sphere at residue 4) to red at the C-terminus (identified by 
a red sphere at residue 389). The three domains of each monomer are 
defined as the N-terminal helix (deep blue), the central catalytic domain and 
the C-terminal domain (encompassing the orange and red structural elements 
on the edges of this figure). The external aldimine present in each active site 
is drawn in space filling mode.  
3.3 Scale-up of reaction 
To identify the product trapped inside the structure, the ternary complex was 
analysed by the mass spectrometry after the enzyme was incubated with 
PLP, threonine and decanoyl-CoA. Because the chemical nature of CAI-1 is 
very volatile and the reaction volume in one ml was not sufficient to identify 
the compound after chemical extraction after incubation (on ice for 60 minutes 
followed by incubation in room temperature for another 60 minutes), the 
following mixtures (Table 3.1) were made in a 10 ml glass test tube to prevent 
any contaminant that could come from plastic wares (Verge and Agnes 2002). 
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The reaction mixtures were then extracted into organic solvent 
(dichloromethane), which was then subjected to mass spectrometric analysis 
Table 3.1 Scale-up of reaction for extraction of the reaction mixture  
Buffer 20 mM HEPES, pH 7.5 + 
200 mM NaCl 
20 mM HEPES, pH 7.5 + 200 
mM NaCl 
Amino acid L-Threonine (Final 
concentration of 5 mM) 
L-2-amino butyric acid 
(Final concentration of 5 mM) 
Fatty acyl-
co-A 
Decanoyl co-A (Final 
concentration of 500 µM) 
Decanoyl co-A (Final 
concentration of 500 µM) 
 
Mass spectrometry of enzyme products 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.A Mass spec analysis of reaction mixture using L-threonine as 
major substrate 
Selected m/z region of the ESI MS analysis of a dichloromethane extract from 
the incubation of CqsA with L-threonine, PLP and decanoyl-CoA (top), control 
sample containing methanol only (bottom pannel). One major new peak was 
observed with m/z = 186.2 Da. 
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From the reaction mixture of PLP, L- threonine and decanoyl-CoA the major 
peak of product detected was compound 186.2 Da in mass which 
corresponded to the expected mass of α-amino ketone (Figure 3.3.A). The 
result was also consistent with the product detected in the crystal as the 
binary external aldimine. No peak was observed corresponding to β-hydroxy-
amino ketone (Figure 2.1). From the reaction mixture of PLP, L-2-
aminobutyric acid and decanoyl-CoA the major product mass detected was 
214 Da that corresponded to the expected α-amino ketone (Figure 2.1 and 
Figure 3.3.B). Although a peak at the same region of mass tend to complicate 
the analysis, it got clarified after analysis of the data at high resolution as the 
same mass was also seen in the control sample (Figure 3.2.A).  
 
 
 
 
 
 
 
Figure 3.3.B Mass spec analysis of reaction mixture using L-2-aminobutyric 
acid - as major substrate 
Incubation of CqsA, L-2-aminobutyric acid, PLP and decanoyl-CoA diluted in 
methanol analysed by ESI MS with glycylglycylalanine, [M+H]+ 204.0984 as 
lock mass (top).  Methanol blank injection showing n-butyl 
benzenesulfonamide (plasticiser), [M+H]+ 214.0916/ 0893. 
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3.4 Discussion 
The crystal structure of CqsA and the assay performed with the purified 
protein confirms that it is a member of the PLP-binding family of α-oxoamine 
synthases (AOS). The basic catalytic process performed by this family of 
enzymes involves the condensation of an amino acid with an acyl-CoA 
thioester. Decanoyl-CoA was presumed to be the acyl-CoA thioester 
substrate for CqsA from the length of carbon chain in CAI-1, but the prediction 
of the amino acid substrate became complicated because of the activity of 
CqsA with both 2-aminobutyric acid and L-threonine used in the study. 
In the external aldimine ternary complex as observed in the crystal structure, 
the C10 acyl chain in the CqsA is accommodated in a hydrophobic pocket, and 
displays a great similarity to the binding of the product aldimine observed in 
the crystal structure of AONS complexed with 8-amino-7-oxononanoate (PDB 
code 1DJ9) (Webster et al., 2000). Because hydroxyketone products of CqsA 
when expressed in E. coli, never have a chain length longer than C13 (Higgins 
et al., 2007; Spirig et al., 2008) and the ternary complex observed in the 
crystal structure showing the tunnel accommodating the C10 acyl chain in 
CqsA has a restriction of ~ 3Å just below the acyl chain formed by residues 
His30, Val32, Phe257*, Ile263*, Cys346 and Pro348 (Figure 3.2.D) it became 
more certain that the product would not be longer than C13 chain length.  
In the apo structure, the electron density for residues 69 to 86 was poorly 
defined. In the presence of the external aldimine, the electron density for 
these residues became more continuous, indicating that this region became 
more ordered upon substrate binding. Residues from this region form an 
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extensive loop at one side of the active site, including Phe79 that forms part of 
the hydrophobic acyl-chain containing pocket (Figure 3.2.A and 3.2.B), the 
loop is on the opposite side to the tunnel through which the acyl chain of 
decanoyl-CoA may enter the active site, as observed in the homologous 
protein ALAS in complex with succinyl-CoA (Astner et al., 2005). It is possible 
that this region being disordered facilitates the release of the product. This 
possibly explains the destruction of crystals of CqsA incubated with PLP, L-2-
aminobutyric acid and decanoyl-CoA as a consequence of this region 
becoming disordered and allowing expulsion of the product. 
In the ternary complex of external aldimine, the side chain of L-threonine was 
missing, suggesting the formation of α-amino ketone (Figure 3.4, 5). The 
result was consistent with the mass spectrometry result after extraction of the 
large-scale reaction mixture where a major new peak with m/z = 186.2 Da 
appeared that was not present in the control sample (Figure 3.3.A). The 
formation of 5 is believed to be the result from a retro-aldol reaction of the 
enzyme bound intermediate. This would result in the formation of intermediate 
B or a related intermediate (not shown) in which the decanoyl-CoA is not 
bound. Subsequent protonation of intermediate B in the absence of decanoyl-
CoA, (Path A, Figure 3.4.A) would give one of the two external aldimine 
complexes observed in this study (complex C, Figure 3.4.A).  Alternatively, 
intermediate B could react with decanoyl-CoA (if present) leading to the 
formation of the second external aldimine after a series of reactions (Path B, 
Figure 3.4.A). Release of α-amino ketone 5 could then occur following 
hydrolysis of the iminium functionality present in complex D.  
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The possible reaction mechanism is less complicated with L-2-aminobutyric 
acid as the substrate. A retro-aldol reaction is not possible in this case and the 
production of an α-amino ketone (4a, Figure 2.1) is straightforward. Because 
CqsA can use both L-threonine and L-2-aminobutyric acid as substrate it can 
be concluded that this enzyme has a strong preference for amino acid 
substrates with an ethyl or functionalised ethyl side chain.  
 
 
 
 
 
 
 
 
Figure 3.4 Proposed enzymatic pathway catalysed by CqsA 
(A) A possible rationalization for the formation of complex D and 5. (B) A 
possible side reaction that could lead to the formation of complex E and 
subsequently the diketone 6. 
Although the total pathway of CAI-1 biosynthesis by CqsA is not clear but it 
could be speculated that using L-threonine as a substrate for CAI-1, 
elimination of hydroxide/water and loss of CO2 from a L-threonine-bound 
enzyme intermediate (e.g. complex E, Figure 3.4.B) could occur leading to the 
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production of complex F (Figure 3.4.B). Subsequent hydrolysis of complex F 
could result in release of di-ketone 6. Based on the above experiments, it can 
also be speculated that CAI-1 is biosynthesised via the α-amino ketone 4a 
from L-2-aminobutyric acid, which is subsequently converted to diketone 6. 
It is also possible that CqsA forms a diketone precursor of CAI-1 and that 
would require an additional keto-reductase enzyme to reduce the keto group 
to form the final CAI-1. Alternatively the CqsA may have a broader range of 
substrate preference and none of the above substrates is the actual substrate 
for CAI-1 synthesis. 
3.4.1 (S)-adenosylmethionine (SAM) as a substrate of CqsA 
In a recent paper (Wei et al., 2011) reported that (S)-adenosylmethionine 
(SAM) is one of the two biosynthetic substrates for CqsA. According to their 
mechanism: CqsA couples SAM and decanoyl-CoA to produce a previously 
unknown but potent quorum-sensing molecule, 3-aminotridec-2-en-4-one (Ea-
CAI-1) (Figure 3.5).  
 
Figure 3.5 Enzymatic reaction using SAM as a substrate 
Wei et al., proposed the CqsA mechanism as an unique pathway that 
combines two enzymatic transformations, a β,γ-elimination of SAM and an 
 54	  
acyl transferase reaction into a single PLP-dependent catalytic process. Ea-
CAI-1 is subsequently converted to CAI-1, presumably through the 
intermediate tridecane-3, 4-dione (DK-CAI-1). It was also proposed that Ea-
CAI-1 to DK-CAI-1 conversion occurs spontaneously, and they were also able 
to identify the enzyme responsible for the subsequent step: conversion of DK-
CAI-1 into CAI-1 (Figure 3.6). 
 
 
 
 
 
 
Figure 3.6 Structures of CAI-1-type molecules 
CAI-1, (S)-3-hydroxytridecan-4-one; Am-CAI-1, (S)-3-aminotridecan-4-one; 
Ea-CAI-1, 3-aminotridec-2-en-4-one; and DK-CAI-1, tridecane-3, 4-dione are 
shown (Wei et al., 2011) 
They found that SAM is the substrate for the synthesis of at least three 
different classes of quorum sensing signal molecules, which indicates that 
bacteria have evolved a strategy to utilize an abundant substrate for multiple 
signaling purposes. 
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CqsA is the CAI-1 synthase, which was previously been identified to be (S)-3-
hydroxytridecan-4-one (Figure 2.1). CqsA functions as a pyridoxal phosphate 
(PLP)-dependent aminotransferase-like enzyme. In vitro, CqsA can use L-2-
amino butyrate L-amino butyrate and decanoyl-CoA to produce (S)-3-
aminotridecan-4-one (Am-CAI-1), as was shown in our study discussed above 
and that we published (Jahan et al., 2009). This was subsequently confirmed 
by the Bassler group (Kelly et al., 2009).  
However, in 2011 the Bassler group (Wei et al., 2011) demonstrated that SAM 
is a better substrate than L-amino butyrate (in vitro). CqsA can ligate SAM 
and decanoyl-CoA while eliminating (S)-methyl-5ʹ′-thioadenosine (MTA) and 
coenzyme en-4-one (Ea-CAI-1) (Figure 3.7). They have shown by isotope 
labeling experiments that SAM is used in vivo by CqsA to make CAI-1. Their 
investigation of the conversion of Ea-CAI-1 to CAI-1 suggests that the 
intermediate molecule, DK-CAI-1 (Figure 3.6), is formed and that this reaction 
could happen spontaneously. Consistent with this idea, they have been 
unable to identify any enzyme capable of catalyzing this reaction. The enzyme 
VC1059 is required to convert DK-CAI-1 to CAI-1. They (Wei et al., 2011) 
found that CqsA is capable of directly processing SAM as a substrate in the 
absence of decanoyl-CoA. By analyzing the incubated products in high-
resolution mass spectrometry (HRMS) they were able to identify a product 
with molecular ions of 102.0545, which they presumed to be vinyl-glycine (V-
Gly) or 1-aminocyclopropyl-glycine (Cy-Gly) and 298.0970 for MTA. Because 
Cy-Gly is the reported elimination product of SAM by the enzyme 1-
aminocyclopropyl-glycine synthase (ACCS) and V-Gly is an alternative 
substrate and mechanism-based inhibitor of ACCS, they concluded that CqsA 
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does not act on decanoyl-CoA in the absence of SAM. They also found that 
CqsA produces V-Gly/Cy-Gly directly from SAM suggests a two-step reaction 
process:  
In the first step, V-Gly/Cy-Gly is formed and this intermediate either remains 
bound or is released and then rebound by CqsA along with decanoyl-CoA in 
the subsequent acyl transferase reaction. They have used kinetic studies, 
spectrometry studies and HRMS analyses to determine that the intermediate 
is indeed V-Gly. They have proposed two possible Schemes: 
Scheme 1: Proposed CqsA reaction scheme 
 
Figure 3.7 Scheme 1 Proposed for CqsA reaction (Wei et al., 2011) 
In scheme-1, reaction of CqsA using SAM and decanoyl-CoA as substrates, 
Wei et al., proposed a reaction sequence that combines a β,γ-elimination of 
SAM with the release of MTA and an acyl transferase reaction with the 
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release of CoA. V-Gly is likely an enzyme-bound intermediate (boxed). The 
lysine amino moiety in the figure depicts the active site Lys236 residue on 
CqsA. They proposed in Scheme 1 that it is possible that MTA elimination 
may happen after the ligation of the CoA thioester onto SAM. They 
unequivocally showed that VC1059 and its homologues could convert DK-
CAI-1 to CAI-1in vitro. Mutation of the vc1059 gene encoding a short chain 
dehydrogenase enzyme results in significantly impaired conversion of DK-
CAI-1 to CAI-1 and, importantly, also Ea-CAI-1 to CAI-1, which supports the 
role of DK-CAI-1 as an intermediate in the biosynthesis of CAI-1 (Scheme 2). 
Although VC1059 appears to be the predominant enzyme that can do the 
conversion of DK-CAI-1 to CAI-1, other VC1059 homologues, namely, 
VC2021 and VCA0301 are also capable of reducing DK-CAI-1to CAI-1 but 
with lower efficiency in vitro. 
Scheme 2: CAI-1Biosynthesis scheme 
 
 
 
 
 
 
Figure 3.8 Scheme 2 Proposed for CqsA reaction (Wei et al., 2011) 
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According to Wei et al., SAM and decanoyl-CoA are the in vivo substrates for 
CqsA, which produces Ea-CAI-1, MTA, and CoASH. Ea-CAI-1 is converted to 
CAI-1 through the intermediate DK-CAI-1. Suggesting that conversion of Ea-
CAI-1 to DK-CAI-1 occurs spontaneously. VC1059 is the primary enzyme 
responsible for converting DK-CAI-1 to CAI-1 (Figure 3.8). 
The study by Wei et al., raised the question of why such a complicated 
synthetic route should exist for CAI-1, particularly given that the immediate 
product of CqsA, Ea-CAI-1, potentially induces quorum sensing.  
A possible explanation is that the physical properties of CAI-1 allow it to 
persist in the environment longer than Ea-CAI-1, which is sensitive to 
hydrolysis to produce DK-CAI-1.  
A second possible advantage of this system is that regulation of the 
conversion enzymes could allow fine-tuning of the precise combination of 
molecules present during quorum sensing. For example, induction of 
enzymes converting DK-CAI-1 to CAI-1 could increase production of the 
potent agonist CAI-1 from the weak agonist DK-CAI-1 and as a consequence 
it could promote a stronger quorum sensing response. 
 
 
 
 
 
 
 59	  
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Structural studies of CqsS 
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4. Structural studies of CqsS  
4.1 Introduction to CqsS 
CqsS, or VCA0522, is the receptor for CAI-1. The focus of this chapter is to 
describe the expression and purification of several constructs of CqsS for 
structural studies. From earlier studies (Henke and Bassler 2004b), CqsS  
was predicted to be a membrane protein that functions as a cell surface 
receptor protein. It has six trans-membrane helices coiled into the lipid bi-layer 
in the outer membrane of the bacteria followed by the cytoplasmic histidine 
kinase domain and a cytoplasmic receiver domain (Figure 4.1.A). There is 
also a variable region in the cytoplasmic region that connects the histidine 
kinase domain to the response regulator receiver domain. Full length CqsS is 
686 amino acids long and was predicted to have the following structure from 
earlier studies (Henke and Bassler 2004b), and by the use of several 
bioinformatics analyses (Figure 4.1.B). Therefore several constructs were 
made: the whole of CqsS (construct 1), the cytoplasmic histidine kinase 
domain (construct 2), the histidine kinase + receiver domain (construct 3), and 
the receiver domain alone (construct 4). The crystal structure of this last 
domain was determined. 
 
 
 
Figure 4.1.A CqsS (cartoon presentation) 
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Figure 4.1.B Predicted Trans membrane region of VCA0522 (Center for 
Biological Sequence Analysis, The Technical University of Denmark) 
A recent study by (Ng et al., 2010) using a combined chemical-genetic 
strategy found that the first three helices of the trans membrane region have 
some clusters of conserved amino acids that are essential for ligand binding. 
They made a library of mutants (Figure 4.2) and synthesized some CAI-1 
analogues (Figure 4.3) to determine the specific amino acids that play a vital 
role in ligand recognition and binding.  
They discovered that residues W104 and S107 could specify the C3 moiety 
present in the ligand, which is the basis of the CqsS receptor’s ability to 
discriminate between CAI-1 and amino-CAI-1. They used both native CAI-1 
and its synthetic analogues (Figure 4.3) to demonstrate that residue F162 
plays a role in restricting the size of the ligand head group and C170 
contribute in recognition of tail length. Because residues W104 and S107 are 
located in the fourth trans-membrane region, N-terminal region (first half) was 
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considered as the most conserved region, which is common to all CqsS 
receptors.  
They identified the C-terminal region of the CqsS trans-membrane domain as 
less conserved because its function is species specific. 
 
 
 
 
 
 
 
Figure 4.2 CqsS mutants and their corresponding phenotypes 
CqsS is predicted to contain six trans-membrane helices. Mutant receptors 
studied in the work by Ng et al., are color coded according to their 
phenotypes: green, more sensitive to CAI-1 (lower EC50 than WT CqsS); 
blue, less sensitive to CAI-1 (higher EC50 than WT CqsS); red, no change in 
sensitivity to CAI-1; gray, specificity switch phenotype (Ng et al., 2010). 
 63	  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Natural and synthetic CqsS ligands 
CAI-1 and amino-CAI-1 are naturally produced and detected by V. cholerae. 
P-CAI-1, C8-CAI-1, methyl-P-CAI-1, and C8-P-CAI-1 are synthetic 
compounds (Ng et al., 2010). 
Based on their knowledge of the functional roles of the conserved amino acid 
residues F162 and C170 Ng et al., proposed a model for CAI-1 and CqsS 
interaction (Figure 4.4) These two residues are located in the C-terminal end 
of the trans-membrane region which is just upstream of the histidine kinase 
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region, Ng et al., suggested these two residues could be involved to play a 
vital role in the down stream histidine kinase activity because of their ability to 
restrict the size of the CAI-1 binding site.  
 
  
 
 
 
 
Figure 4.4 Model for CqsS-CAI-1 ligand-receptor interactions 
(A) In WT CqsS, the polar head group and the hydrophobic tail of CAI-1 
interact, perhaps directly, with F162 and C170, respectively. These 
interactions are required to inhibit CqsS kinase activity. (B) Small amino acid 
residue (e.g., cysteine, alanine) is required at position 162 to permit 
productive interaction of CqsS with P-CAI-1. (C) Bulky residue (e.g., tyrosine, 
phenylalanine) is required at position 170 to promote interaction between 
CqsS and C8-CAI-1. (D) Combination of a small residue at position 162 and a 
bulky residue at position 170 confers an interaction between CqsS and C8-P-
CAI-1 (Ng et al., 2010). 
4.1.1 Cloning of full length CqsS (construct-1) 
Primers (purchased from Eurogentec, Belgium) were designed specifically for 
pWaldo-GFPe vector (Appendix I-3) and contained specific recognition sites: 
KpnI in the forward primer (5ʹ′- TGCAGGTACCATGATAGTGAGC - 3ʹ′) and 
BamHI site in the reverse primer (5ʹ′- GAAGGGTAGGATCCCACCCAA - 3ʹ′). 
Amplification of the gene was carried out by PCR from genomic DNA of V. 
cholerae O1 El Tor strain N16961 using standard protocol (Appendix I-5). 
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After the amplification by PCR, the sample was checked by running in 
agarose gel electrophoresis (Appendix I-6) (Figure 4.5.A) with appropriate 
DNA ladder and the positive sample band was excised from the gel and 
purified by Gel Extraction Kit (Promega).  
The purified DNA of both the PCR product and the vector was then double 
digested with corresponding restricting endo-nuclease enzyme (Fast Digest, 
Fermentas) following the supplier’s protocol (as described in Appendix I-7) 
followed by ligation with T4 DNA ligase (Fermentas) (Appendix I-8). Positive 
colonies were identified by colony PCR (Appendix I-10) (Figure 4.5.B) and an 
overnight culture of DH5α was grown. From overnight cultures of DH5α cells, 
plasmids were isolated and sent for sequencing at the sequencing service at 
the School of Life Sciences, University of Dundee, Scotland 
(www.dnaseq.co.uk). In the mean time, purity of the sample was also checked 
by using the gel extracted DNA as a template and running PCR with 
construct-2, 3 and 4 primers as internal primers. The result showed that PCR 
products of the correct size were amplified, in addition to some non-specific 
products (Figure 4.5.C). 
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Figure 4.5 Agarose gel electrophoresis of vca0522 (full length cqsS) 
(A) Amplification of vca0522 gene from genomic DNA of V. cholerae (using 
primer set 1). M, 1 kb DNA ladder (Promega); lane 1, amplification of vca0522 
gene product. (B) Colony PCR of cloning vector pWaldo-GFPe contains 
vca0522 gene. Lane 1, colony PCR product of pWaldo-GFPe vector 
containing vca0522 gene. (C) PCR of gel extracted DNA with internal primers. 
Lane 1,primer for construct 1; Lane 2, primer for cons-2; Lane 3, primer for 
cons-3; Lane 4, primer for cons-4. 
The sequencing result was satisfactory so the plasmid was transformed into 
the expression hosts BL21 (DE3), Rosetta  (DE3) and C43 (DE3) cells using 
the standard protocol (Section I-9). A transformed expression host colony was 
used to inoculate 10 ml LB containing kanamycin (50 mg/ml) followed by 
shaking incubation at 37 °C overnight. After incubation, 200 µl culture was 
inoculated into 10 ml LB containing kanamycin followed by shaking incubation 
at 37 °C for 2-3 hours until an OD600 of 0.5-0.6 was reached. The cells were 
then divided into several aliquots and subjected to various conditions to 
induce the expression of soluble CqsS protein (Table 4.1). 
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Table 4.1 Conditions used for the induction of expression of CqsS 
 
Unfortunately, there was no expression at all in any of the samples and at this 
point it was believed that the distance of the initiation codon from the 
ribosome-binding site was too far for efficient expression (Chen et al., 1994). 
A second set of primers was therefore designed, with XhoI for the forward 
primer (5ʹ′- TGCACTCGAGATGATAGTGAGC -3ʹ′), while the reverse primer 
contained BamHI. Following the same protocol of PCR, restriction digestion, 
ligation and transformation into DH5α cells, the plasmid was sequenced 
(Figure 4.6). 
 
 
 
 
Figure 4.6 Agarose gel electrophoresis of vca0522 (full length cqsS) 
(A) Amplification of vca0522 gene from genomic DNA of V. cholerae (using 
primer set 2). M, 1 kb DNA ladder (Promega); lane 1, amplification of vca0522 
gene product. (B) Colony PCR of cloning vector pWaldo-GFPe contains 
vca0522 gene. Lane 1, colony PCR product of pWaldo-GFPe vector 
containing vca0522 gene. 
Expression 
(Shock) 
Expression 
Host 
(E. coli) 
Incubation 
Temperature 
 
Incubation 
Time 
IPTG 
Concentration 
Heat shock 
or 
Cold shock 
or 
No shock 
Rosetta (DE3) 
or 
BL21 (DE3) 
or 
C43 (DE3) 
37 °C 
 
or 
 
25 °C 
3 hours 
 
or 
 
18 hours 
1.0 mM 
 
or 
 
0.5 mM 
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Unfortunately, the result of the DNA sequencing showed that it was not the 
gene of interest; it was an E. coli gene. The same PCR protocol was repeated 
several times but a clean 2kb gene product could not be obtained. So primer 
set-3 (long primers) was designed (Table I-6). 
The gene starts with “gtg” instead of “atg”, so three sets of forward primers 
were designed to see if any change of the sequence really made any 
difference during the PCR. The PCR was performed in the same way (as 
described in section I-5) for all three of the samples at the same time but only 
primer set-2 gave a nice clean 2kb band whereas the other two samples gave 
nothing (Table I-4.2, Figure 4.7.A) when the sample were checked in agarose 
gel. The 2 kb band was excised from the gel and the DNA was extracted with 
the DNA extraction kit according to the manufacturers protocol and the purity 
of the DNA was checked using the internal primers designed for specific 
regions: TM for Trans membrane region, HK for histidine kinase region and 
RV for receiver domain (Table I-7, Figure 4.7.B). 
 
 
 
 
Figure 4.7 Agarose gel electrophoresis of vca0522 (full length cqsS) 
(A) Amplification of vca0522 gene from genomic DNA of V. cholerae (using 
primer set 3). M, 1 kb DNA ladder (Promega); lane 1,PCR with long primer-1; 
lane 2,PCR with long primer-2; lane 3,PCR with long primer-3. (B) PCR of gel 
extracted DNA with internal primers. Lane TM, PCR with long primer-TM; HK, 
PCR with long primer-HK; RV, PCR with long primer-RV. 
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Gel extracted DNA of PCR product of sample-2 was then used as template for 
four more PCR cycles using long primer set-1 and 3. The two primer sets 
were each tested at concentrations of 5 µM and 50 µM. After the completion 
of the PCR, only 5 µl of each sample was run in agarose gel to check product 
purity and the rest of the reaction mixture was purified in solution using DNA 
extraction kit (Promega) according to the manufacturers’ instructions. 
Although 50 µM of primer concentration gave an unexpected band near 3 KB, 
the product of the PCR reaction was almost clean (Gel not shown). Following 
restriction digestion, ligation and transformation, the results of the DNA 
sequencing were satisfactory when carried out with all of the following 
sequencing primers: 
T7_forward, T7_reverse, TM_forward, TM_reverse, HK_forward, HK_ 
reverse, RV_forward, and RV_reverse. The plasmid was transformed into the 
expression hosts as listed in Table 4.1 for expression trials. 
For small-scale expression trial, 200 ml of LB and TPB were inoculated with 
0.2% of overnight culture of expression host into separate flasks with 
kanamycin and followed by shaking incubation at 37 °C for 2-3 hours until an 
OD600 of 0.5 - 0.6 was reached. The cells were then divided into several 
aliquots and subjected to various conditions to induce the expression of 
soluble CqsS protein (Table 4.1, Figure 4.8). 
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Figure 4.8 Expression trial of GFP fused construct-1 protein in C43 cells 
(A) Soluble fraction (B) whole cell fraction M, protein marker (Mark12™, 
Invitrogen); lane 1-3, cold shock, heat shock, no shock and incubated at 
20 °C; lane 4-6, cold shock, heat shock, no shock and incubated at 25 °C. 
lane 7-9, cold shock, heat shock, no shock and incubated at 30 °C; lane 10-
12, cold shock, heat shock, no shock and incubated at 37 °C. 
There was no over expression of CqsS and in some of the aliquots incubated 
at 25°C, there appeared to be clear signs of cell death instead. This indicates 
that the protein is very toxic and as soon as the protein starts to be 
expressed, the cells start to die. A cell-free expression system (The TNT T7 
Quick Coupled Transcription/Translation System by Promega) was therefore 
tested with the help of Dr Garry Luke (Professor Martin Ryan’s group). 
However, the results were negative even with the positive control (Figure 4.9). 
It was presumed that the level of purity of the plasmids was not good enough 
to test them in the cell free system and plasmid purification by phenol-
chloroform extraction was recommended prior to running the sample in the 
cell free system. 
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Figure 4.9 Cell free expression trial of GFP fused CqsS constructs 
(A) (Promega) DNA extraction kit purified plasmid (B) Chloroform-et-OH 
extracted plasmid; lane 1,Lab control; lane 2, construct-1 with primer set1; 
lane 3, construct-1 with primer set 2; lane 4, construct-1 with primer set 3; 
lane 5, Construct-3 used as a positive control. 
Unfortunately, no expressed product could be detected, even by western 
blotting. The plasmids were then inserted into BL-21 E. coli cells and induced 
to grow and express proteins at temperatures as low as 25 °C and 30 °C. The 
samples looked green in colour that suggested expression of the GFP but 
because 1.5% of DDM was added to extract the membrane protein from the 
cell debris, the mass spec could not pick the correct mass from the 
background signal of the detergent. The GFP looked green in the fluorescent 
microscope but when run in SDS, did not give the correct mass because of 
the presence of the detergent. The sample was then run in a native gel and in 
a SDS gel (Figure 4.10). 
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Figure 4.10 Expression trial of GFP fused construct-1 
(A) Native gel; lane 1,Positive sample1; lane 2, Positive sample2; lane 3, 
Marker; lane 4, GFP fused full length CqsS; lane 5, Duplication of sample 4. 
(B) SDS-PAGE; lane 1, Marker; lane 2, sample1; lane 3, sample2. 
The bands were then cut and sent for mass spec analysis. Unfortunately, they 
were still too contaminated with DDM and too weak signal of protein such that 
only some E. coli proteins could be identified from the samples. 
To prevent the cell death due to the toxic effect of the membrane protein 
expression, cells were induced with very low concentration of IPTG (200 µM) 
and incubated at a low temperature to express the membrane protein at a 
slow rate (over a period of 24 hours) (Table 4.2) 
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Table 4.2 Conditions used for the soluble expression of CqsS 
Media TPB LB NZY Minimal 
OD600 at 
induction 
0.5 0.5 0.6 0.07 
Incubation 
temperature 
20 °C 20 °C 20 °C 20 °C 
Incubation 
time 
23 h 23 h 23 h 23 h 
Final OD600 
 
+++++ 2.8 2.53 0.69 
Pellet colour 
 
Green Green Colourless White/colourless 
 
4.1.2 Purification of full-length membrane protein CqsS (construct-1)  
At the end of the period of the growth, the cell pellets were harvested using 
the normal procedure and resuspended in a buffer composed of 50 mM Tris-
HCl (pH 7.6), EDTA (50 mM), Glycerol 10%, DTT (0.5mM) in the presence of 
protease inhibitor and DNase and sonicated on ice. Following centrifugation 
for 20 min at 24000g at 4 °C, the soluble fraction that contained the 
membranes (Drew et al., 2001) was resuspended in the same buffer + 1.5% 
DDM) overnight with rolling at 4 °C and was centrifuged in an ultracentrifuge 
(Beckman L-60) at a maximum speed of 40,000g per hour for three hours. 
Both the pellet and the supernatants were green in color and were checked in 
the SDS-PAGE (Figure 4.11). 
Because the existing buffer and the presence of detergent made the protein 
too thick to be loaded into the gels, it was necessary to change the buffer 
composition to citrate buffer + 500 mM / 1M NaCl and the volume of the 
protein sample from 20 µl to 1 ml.  
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Figure 4.11 Expression trial of GFP fused CqsS constructs 
M, protein marker (Mark12™, Invitrogen); lane 1, cell lysate after IPTG 
induction; lane 2, supernatant after first sonication; lane 3 supernatant after 
second sonication; lane 4, pellet after second sonication; lane 5-8 is same as 
1-4 except the salt concentration is 1M instead of 500mM. 
The sharp protein bands of the expected molecular weight (104 KDa) were 
cut and sent for mass spec analysis (Figure 4.12). 
 
 
 
 
 
Figure 4.12 Peptides matched during mass spectrometry analysis of CqsS 
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4.2 Cloning, expression, purification and crystallization trials of histidine 
kinase domain (construct-2) 
4.2.1 Cloning of the histidine kinase domain 
Construct-2, which consists of the histidine kinase domain (residues 173 to 
416 of CqsS) is 244 amino acids in length with a molecular weight of 
approximately 27.4 kDa and calculated isoelectric point (pI) of about 5.6. 
Primers (purchased from Eurogentec, Belgium) were designed specifically for 
pWaldo-GFPe vector (section I-3) (Table I-4.1) and contained specific 
recognition sites KpnI in the forward primer (5ʹ′- 
TGTGGTACCATGAACCAAAT CTC - 3ʹ′) and BamHI site in the reverse 
primer (5ʹ′- TCGTTAACCGGGATCCAATCGT - 3ʹ′). Amplification of the gene 
was carried out by PCR from genomic DNA of V. cholerae O1 El Tor strain 
N16961 using standard protocol (section I-5). After the amplification by PCR, 
the sample was checked by running in the agarose gel electrophoresis 
(section I-6, Figure 4.13.A) with appropriate DNA ladder and the positive 
sample band was excised from the gel and purified by Gel Extraction Kit 
(Promega). The purified DNA of both the PCR product and the vector was 
double digested with corresponding restricting endo-nuclease enzymes (Fast 
Digest, Fermentas) following the supplier’s protocol (as described in section I-
7) followed by ligation with T4 DNA ligase (Fermentas) (section I-8).  
Positive colonies were identified by colony PCR (section I-10) followed by 
double digestion and an overnight culture of DH5α was grown. From the 
overnight culture of DH5α cells, plasmids were isolated and further confirmed 
by double digestion with corresponding restricting endo-nuclease enzymes 
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(Fast Digest, Fermentas) following the supplier’s protocol (section I-7, Figure 
4.13.B). The Plasmid containing the insert was sent for sequencing to the 
sequencing service at the School of Life Sciences, University of Dundee, 
Scotland (www.dnaseq.co.uk). The plasmid was then transformed into the 
expression hosts BL21 (DE3), Rosetta  (DE3) and C43 (DE3) cells using the 
standard protocol described earlier. The cells were then grown and induced 
for protein expression (section II-1, Table II-1). 
There was no over-expression of any protein of desired protein. After 
checking all the other parameters, it was confirmed that the restriction site 
KpnI selected for cloning was a little too far away from ribosome binding site 
in the vector used (Chen et al., 1994). 
 
 
 
 
 
Figure 4.13 Agarose gel electrophoresis of construct-2 (histidine kinase)  
(A) Amplification of vca0522_histidine kinase gene from genomic DNA of V. 
cholerae (using primer set 3). M, 1 kb DNA ladder (Promega); lane 1, 
amplification of vca0522_histidine kinase gene product. (B) Double digestion 
of clone positive plasmid. Lane 1, double digested vector and insert (vector 5 
kb and insert 729 bp). 
At this point, primer set 2 was designed for the same plasmid but with a 
different restriction cleavage site, XhoI for the forward primer (5ʹ′- 
TGTCTCGAGATGAACCAAAT CTCT -3ʹ′), while the reverse primer was the 
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same. Following the same protocol of PCR, restriction digestion, ligation and 
transformation into DH5α cells, and the plasmid was sent for sequencing. 
The result of the DNA sequencing showed there was an error in the designing 
of the reverse primer, which provided an extra “t” at the 3ʹ′-end of the gene 
that caused the termination of protein synthesis immediately after histidine 
kinase and before synthesis of green fluorescent protein. This also explained 
the result of an initial expression trial, which produced the histidine kinase 
domain with no GFP (Figure 4.14). 
 
 
 
 
 
 
 
 
 
Figure 4.14 Cloning and expression trial of construct-2 (histidine kinase) 
(A) Amplification of vca0522_hiskinase gene from genomic DNA of V. 
cholerae (using primer set 2). M, 1 kb DNA ladder (Promega); lane 1, 
amplification of vca0522_hiskinase gene product. (B) Colony PCR of cloning 
vector pWaldo-GFPe containing vca0522_hiskinase gene. Lane 1, colony 
PCR product of pWaldo-GFPe vector containing vca0522_hiskinase gene 
(1.7kb). (C) Expression of 28 kDa histidine kinase protein without the GFP (27 
kDa) tag. 
For the correction of the reading frame of the full-length histidine kinase fused 
with the green fluorescent protein, one set of primer was designed in the web 
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based program of “The Quick-change® Lightning Site-Directed Mutagenesis”  
(STRATAGENE). 
Forward-5'-ATTGAGCTTTCCTCGTTACGAT-GGATCCGAAAACC-3' 
Reverse-3'-TAACTCGAAAGGAGCAATGCTA-CCTAGGCTTTTGG-5' 
After the mutagenesis had been performed, the plasmid was sent for 
sequencing and result showed that the mutation had corrected the reading 
frame. In the expression trial, a full-length 55 kDa protein of histidine kinase 
fused with the GFP was expressed and was also detected in the culture fluid 
as a vibrant green fluorescent color (Figure 4.15). Unfortunately, the protein 
was not soluble. Even 1% detergent DDM (n-dodecyl-beta-D-maltoside) did 
not solubilize the protein. Some denaturation solution (Chapter 6) was used to 
solubilize the green pellets, but this denaturation process was not an efficient 
method for purification purposes and it was decided that another more 
efficient plasmid was needed to solubilize the protein. 
 
 
 
 
Figure 4.15 Expression trial of GFP fused histidine kinase protein  
M, protein marker (Mark12™, Invitrogen); lane 1, cell lysate after IPTG 
induction; lane 2, supernatant after sonication; lane 3, soluble fraction after 
de-naturation of the green pellets with denaturation buffer; lane 4, insoluble 
fraction after denaturation of the green pellets with denaturation buffer. 
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A maltose binding protein (MBP) fusion has been shown in some cases to 
help solubilise proteins (Fox and Waugh 2003). The vector pLou3 is an 
engineered variant of NEB vector pMAL-c2X that has an N-terminal 6X His-
tag followed by MBP that is cleavable using Tobacco Etch Virus (TEV) 
protease, and a lacZα complementation gene present after the MCS (multiple 
cloning sites) (Dr Louise Major, personal communication). A new set of 
primers was designed with NcoI and BamHI restriction endonuclease 
cleavage sites, which are compatible with the pLou3 vector:  
Hk_F_NcoI 5ʹ′- ATATGCCATGGCTCGTAACCAAATCTCTCATGAGAC-3ʹ′ 
HK_R_BamHI 5ʹ′- GGATTGGATCCCTAATCGTAACGAGGAAAGCTCAAT-3ʹ′ 
Because of the presence of a lacZα gene after the multiple cloning sites, 
positive colonies were identified easily by blue-white screening followed by 
double digestion for further confirmation (section I-10.A, Figure 4.16). 
 
 
 
 
 
 
Figure 4.16 Agarose gel electrophoresis of construct-2 (histidine kinase) 
(A) Amplification of vca0522_hiskinase gene from genomic DNA of V. 
cholerae (using primer set 2). M, 1 kb DNA ladder (Promega); lane 1, 
amplification of vca0522_hiskinase gene product. (B) Double digestion of 
cloning vector pLOU3 containing vca0522_hiskinase gene. Lane 1, double 
digested vector and insert (vector 6.7 kb and insert 729 bp). 
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In the expression trial, good soluble protein expression was observed with 
25 °C overnight incubation in the presence of 1 mM IPTG (section II-1) 
Protein identity was also confirmed by mass spec (section III-1). The 
expression trial was then scaled up to five litres of culture and purified using 
the method described earlier  (Section III-2) using a buffer containing 20 mM 
Tris-HCl pH 7.4, 200 mM NaCl, 10-350 mM Imidazole.  
After two rounds of Ni-column purification followed by gel filtration 
chromatography (section III-2.4) (Figure 4.17) more than 80% pure protein 
was obtained. Unfortunately, as soon as the protein was removed from its 
solubilisation partner MBP, the protein started to become unstable and started 
to form multimers.  
After purification the protein was concentrated up to 5.6 mg/ml using a protein 
concentrator of molecular cut off 10 kDa (MILLIPORE). One ml of pure protein 
was obtained, attempts to concentrate the protein any further caused 
precipitation of the protein, despite the addition of 10% glycerol and other 
protein solubilising reagent (50mM L-arginine and L-glutamic acid) 
(Golovanov et al., 2004). 
Finally, some of the protein 5.6 mg/ml was used for crystal trials and the rest 
was flash frozen using liquid nitrogen and stored at -80° C to use in the future. 
For crystal trials, seven commercially available screens were used and the 
plates were set up using the robot “Honey bee” (Section IV-2). Two different 
protein concentrations were used in the initial screens; the higher 
concentration was 5.6 mg/ml and the lower concentration was 4.5 mg/ml. No 
crystals have been found to date. 
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Figure 4.17 Purification of histidine kinase protein 
 
(A) First Ni2+-affinity column pull down. M, protein marker (Mark12™, 
Invitrogen); lane 1, supernatant after sonication; lane 2, flow-through 
(unbound protein) after loading sample on to the column; lane 3-4, column 
wash with the buffer containing 10 mM imidazole; lane 5-10, elution in buffer 
containing 350 mM imidazole. (B) TEV cleavage of MBP-tagged histidine 
kinase; lane 1, TEV undigested sample of histidine kinase; Lane 2, TEV 
digested sample of histidine kinase. (C) Second Ni2+-affinity column. Lane 1, 
TEV digested sample, pre column; Lane 3-5, flow through containing histidine 
kinase without MBP; Lane 6, elution of MBP. (D) Gel filtration 
chromatography. Lane 1-5, fractions containing pure histidine kinase protein; 
6-9 histidine kinase with MBP. (E) Gel filtration chromatogram for histidine 
kinase. (F) Matched peptides of histidine kinase identified by mass 
spectrometry. 
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4.3 Cloning, expression, purification and crystallization trial of histidine 
kinase + receiver domain (construct-3) 
4.3.1 Cloning construct-3 
Construct-3, consisting of both the histidine kinase domain and the receiver 
domain (CqsS residues 173 to 686), is 514 amino acids in length with a 
molecular weight of approximately 58 kDa and a calculated isoelectric point 
(pI) of about 5.2. With the help of the bio-informatics tool RONN (Yang et al., 
2005), a number of residues of the protein were predicted to be dis-ordered 
(Figure 4.18). 
 
 
 
 
 
 
 
 
 
Figure 4.18 Probability of disordered regions of Construct-3 (using RONN) 
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Primers were designed specifically for pWaldo-GFPe vector (Table I-4.1) and 
contained specific recognition sites KpnI in the forward primer (5ʹ′- 
TGTGGTACCATGAACCAAAT CTC - 3ʹ′) and BamHI site in the reverse 
primer (5ʹ′- AAGGGTAGGATCCCACCCAAG - 3ʹ′)(purchased from 
Eurogentec, Belgium). Amplification of the gene was carried out by PCR from 
genomic DNA of V. cholerae O1 El Tor strain N16961using standard protocol 
(section I-5). After the amplification by PCR, the sample was checked by 
running in agarose gel electrophoresis (section I-6, Figure not shown) with 
appropriate DNA ladder (Promega). 
Unfortunately, the correct gene was not amplified from the genomic DNA and 
due to the distance of the restriction site from the ribosome binding site (Chen 
et al., 1994) a new set of primer was designed for Construct-3 for the same 
plasmid but with a different restriction cleavage site, XhoI for the forward 
primer (5ʹ′- TGTCTCGAGATGAACCAAAT CTCT -3ʹ′), while the reverse primer 
was the same.  
For PCR, instead of using genomic DNA, gel extracted DNA of the full-length 
vca0522 (cqsS) was used as template and after the PCR the sample was 
checked by agarose gel electrophoresis (section I-6, Figure 4.19.A), the 
positive sample band was excised from the gel and purified by Gel Extraction 
Kit (Promega). The purified DNA of both the PCR product and the vector was 
double digested with corresponding restriction endo-nuclease enzymes (Fast 
Digest, Fermentas) following the supplier’s protocol (as described in section 
3.17). This was followed by ligation with T4 DNA ligase (Fermentas) (section 
I-7) and transformed into DH5α cells. Positive colonies were identified by 
 84	  
colony PCR (section I-10, Figure 4.19.B) and an overnight culture of DH5α 
was grown. From an over night culture of DH5α cells, plasmids were isolated 
and sent for sequencing to the sequencing service at the School of Life 
Sciences, University of Dundee, Scotland (www.dnaseq.co.uk). The plasmid 
was then transformed into the expression hosts BL21 (DE3), Rosetta  (DE3) 
and C43 (DE3) cells using the standard protocol described earlier. The cells 
were then grown and induced for protein expression (section II-1, Table II-1, 
Figure 4.19.C). 
 
 
 
 
 
 
 
Figure 4.19 Cloning and Expression trial of GFP fused Construct-3 protein 
(A) Amplification of gfp fused construct-3 gene (using primer set 2 and gel 
extracted DNA). M, 1 kb DNA ladder (Promega); lane 1, amplification of 
construct-3 gene product. (B) Colony PCR of cloning vector pWaldo-GFPe 
contains construct-3 gene. Lane 1, colony PCR product of pWaldo-GFPe 
vector containing construct-3 gene (2.5kb). (C) Expression of 85 kDa 
Construct-3 protein fused to GFP tag. M, protein marker (Mark12™, 
Invitrogen); lane S, supernatant after sonication; lane W, whole cell lysate 
after sonication. 
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Because the GFP fusion was not able to solubilize the protein, it became 
necessary to use more efficient solubilising protein like MBP (Fox and Waugh 
2003). Another set of primers was designed for pLou3 vector (Section I-3, 
Table I-5) and designated as Cons3_F_NcoI with the following sequence (5ʹ′- 
ATATGCCATGGCTCGTAACCAAATCTCTCATGAGAC -3ʹ′) and 
Cons3_R_BamHI, (5ʹ′- GTATTGGATCCCTACACCCAAGCTGCCACTTTA -
3ʹ′).  
The PCR was carried out using gel extracted full-length gene of CqsS 
(vca0522) as template DNA using pfu polymerase enzyme (Promega) 
according to manufacturer’s instructions (Section I-5) (Figure 4.20.A) 
Following the same protocol for cloning, as described earlier in this chapter for 
histidine kinase protein, positive colonies were identified by blue-white 
screening and confirmed by double digestion (Section I-10.A, Figure 4.20.B) 
 
 
 
 
 
Figure 4.20 Agarose gel electrophoresis of construct-3 cloned into pLOU3 
plasmid  
(A) Amplification of construct-3 (using primer set 3). M, 1 kb DNA ladder 
(Promega); lane 1, amplification of construct-3 gene product. (B) Double 
digestion of clone positive plasmid selected by blue-white screening. Lane 1, 
double digested vector and insert (vector 5 kb and insert 1.5kb). 
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After confirmation of the correct sequence, the plasmid was used for 
expression trial. In the expression trial (Section II-1) protein expression at 
25 °C overnight seemed to be better than 37 °C for 3-4 hours.  
The optimal condition for the protein expression was then scaled up to five 
litres of cultures for protein purification. Protein from five litres of bacterial 
culture was then purified using the method described (Section III-2) using 20 
mM Tris-HCl pH 7.4, 200 mM NaCl, 10-350 mM Imidazole as the purification 
buffer. 
Again, as seen in the histidine kinase, after two rounds of Ni-column 
purification followed by a gel filtration chromatography (section III-2.4) (Figure 
4.21) there was still some lower molecular weight protein contaminant 
associated with the protein of interest. The protein was therefore concentrated 
again and dialysed against 20 mM Tris-HCl buffer pH 7.4 containing only 20 
mM of NaCl and loaded into an Anion-exchange column (GE Healthcare).  
The column was then attached into an AKTA purification system (GE 
Healthcare) and the protein was eluted with a linear gradient of increasing 
NaCl concentration (Figure 4.22.A, Figure 4.22.B).  
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Figure 4.21 Purification of Construct-3 protein 
(A) First Ni2+-affinity column purification. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4-5, column wash with the buffer containing 10 mM 
imidazole; lane 6-8, elution in buffer containing 350 mM imidazole. (B) TEV 
cleavage of MBP-tagged Construct-3 protein. Lane 2, TEV digested sample of 
Construct-3 protein. (C) Second Ni2+-affinity column. Lane 1, TEV digested 
sample, pre column; Lane 3-4, 50 mM imidazole wash Construct-3 protein 
without MBP. Lane 6, elution containing separated MBP. (D) Eluted 
Construct-3 protein from gel filtration chromatography. (E) Gel filtration 
chromatogram for Construct-3 protein. 
 88	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 Further purification of Construct-3 protein 
(A) Eluted Construct-3 protein after anion-exchange. M, protein marker 
(Mark12™, Invitrogen); lane 1,pre-column; lane 2, flow-through (unbound 
protein) after loading sample on to the column; lane 3-10, elution in buffer 
containing 20-500 mM NaCl. (B) Ion-exchange chromatogram of Construct-3 
protein. (C) Eluted fractions from anion-exchange; lane 1-5, elution in buffer 
containing 250-480 mM NaCl. (D) Ion-exchange chromatogram for Construct-
3 protein in the Bio-cad 700 E HPLC machine. (E) Matched peptides of 
Construct-3 protein identified by mass spectrometry. 
Even after the anion exchange chromatography, the protein was still 
associated with lower molecular weight contaminants and also seemed to 
form multimers after removal from its solubilisation partner MBP. For further 
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purification, the protein was then concentrated and dialysed again in the 
buffer containing 20 mM of NaCl and Loaded into a Bio-cad 700 E HPLC 
machine for elution in a gradient of 0 to 500 mM of NaCl in the same buffer 
(Figure 4.22.C, Figure 4.22.D). Because no significant improvement was 
obtained from the anion exchange procedure, at this stage it was decided to 
continue on to crystallization trials. 
Finally, the protein was concentrated up to 6.5 mg/ml and 1 ml of pure protein 
was obtained. Some of the protein was used for crystal trials and the rest was 
flash frozen using liquid nitrogen and stored at -80 °C. For crystal trials, seven 
commercially available screens were used and the plates were set up using 
the robot “Honey bee” (Section IV-2). Two different protein concentrations 
were used in the initial screens; higher concentration was 6.4 mg/ml and 
lower concentration was 4.6 mg/ml. No crystals have been found to date. 
4.4 Structural study of the receiver domain (construct-4) 
4.4.1 Cloning of construct-4 
The histidine kinase receiver domain (HKRD), construct-4 (residues 564 to 
686 of CqsS), is 122 amino acids in length with a molecular weight of 
approximately 13.87 kDa and a calculated isoelectric point (pI) of about 4.9. 
Amplification of the gene was carried out by PCR from genomic DNA of V. 
cholerae O1 El Tor strain N16961using standard protocol (section I-5). 
Primers (purchased from Eurogentec, Belgium) were designed specifically for 
pWaldo-GFPe vector and contained specific recognition sites KpnI in the 
forward primer (5ʹ′- TTGGGTACCATGCGGCATGA- 3ʹ′) and BamHI site in the 
reverse primer (5ʹ′-AAGGGTAGGATCCCACCCAA- 3ʹ′). 
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After the amplification by PCR, the sample was checked by running in the 
agarose gel electrophoresis (section I-6, Figure 4.23.A) with appropriate DNA 
ladder and the positive sample band was excised from the gel and purified by 
Gel Extraction Kit (Promega). The purified DNA of both of the PCR product 
and the vector was then double digested with corresponding restricting endo-
nuclease enzyme (Fast Digest, Fermentas) following supplier’s protocol (as 
described in section I-7) followed by ligation with T4 DNA ligase (Fermentas) 
(section I-8) and transformed into DH5α cells. From overnight culture of DH5α 
cells, the plasmid was isolated and sequenced. 
 
 
 
 
 
 
 
Figure 4.23 Agarose gel electrophoresis of construct-4 (hkrd region) 
(A) Amplification of vca0522_hkrd gene from genomic DNA of V. cholerae 
(using primer set 1). M, 1 kb DNA ladder (Promega); lane 1, amplification of 
vca0522_hkrd gene product. (B) Colony PCR of cloning vector pWaldo-GFPe 
contains vca0522_hkrd gene. Lane 1, colony PCR product of pWaldo-GFPe 
vector containing vca0522_hkrd gene (1.37bp) 
The plasmid was then transformed into the expression hosts BL21 (DE3), 
Rosetta  (DE3) and C43 (DE3) cells. The cells were then grown and induced 
for protein expression (section II-1, Table II-1). There was no expression of 
the desired protein therefore primer set 2 was designed for the same plasmid 
but with a different restriction cleavage site, XhoI for the forward primer (5ʹ′-
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TTGCTCGAGATGCGGCATGA -3ʹ′), while the reverse primer was the same 
(Figure 4.24). 
Following the same protocol of PCR, restriction digestion, ligation and 
transformation into DH5α cells, and the plasmid was sent for sequencing. 
 
 
 
 
 
 
 
Figure 4.24 Agarose gel electrophoresis of construct-4 (hkrd region) 
(A) Amplification of vca0522_hkrd gene from genomic DNA of V. cholerae 
(using primer set 2). M, 1 kb DNA ladder (Promega); lane 1, amplification of 
vca0522_hkrd gene product. (B) Colony PCR of cloning vector pWaldo-GFPe 
contains vca0522_hkrd gene. Lane 1, colony PCR product of pWaldo-GFPe 
vector containing vca0522_hkrd gene (1.37bp) 
4.4.2 Purification of construct-4 
After cloning the hkrd gene using the XhoI site, soluble expression of HKRD 
fused GFP was achieved by incubation overnight at 25°C in the presence of 1 
mM IPTG (section II-1). The identity of the HKRD was confirmed by mass 
spectrometry (section III-1). The expression trial was scaled up to five litres of 
culture and the protein was purified as described earlier (section III-2, Figure 
4.25). After two rounds of Ni-affinity column and one round of size exclusion 
chromatography by gel filtration, there was still a lot of green fluorescent 
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protein (GFP) associated with the HKRD as well as other lower molecular 
weight protein contaminants. As the isoelectric point of GFP and HKRD are 
quite close (4.9 and 5.5 respectively), they are unlikely to be separated by 
anion exchange. 
 
Figure 4.25 Purification of HKRD (construct4_GFP) protein 
(A) First Ni2+-affinity column. M, protein marker (Mark12™, Invitrogen); lane 1, 
elution in buffer containing 250 mM imidazole. (B) TEV cleavage of GFP+6His 
tagged HKRD. Lane 1, TEV digested sample of HKRD without dialysis; lane 
2, TEV digested sample of HKRD with dialysis. (C) Second Ni2+-affinity 
column. Lane 1, filtered TEV digested sample; lane 2-4, HKRD without 
GFP+6His-tag. (D) Eluted HKRD after gel filtration chromatography. Lane 1-6, 
fractions containing HKRD + GFP and lower molecular weight proteins. (E) 
Gel filtration chromatogram for HKRD. (F) Matched peptides of HKRD 
identified by mass spectrometry. 
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At this point it was necessary to clone the protein into another vector without 
the GFP. Another set of primers was designed that was compatible with both 
of the plasmids pEHISTEV (which encodes an N-terminal 6-His tag) and 
pLou3 (which encodes an N-terminal 6-His tagged MBP) (Section I-3, Table I-
5) and designated as hkrd_F_NcoI with the following sequence (5ʹ′- 
ATATGCCATGGCTAGTCGGCATGAACGACGTATTT-3ʹ′) and 
Hkrd_R_BamHI, (5ʹ′- GTATTGGATCCCTACACCCAAGCTGCCACTTTA-3ʹ′). 
PCR, restriction digestion and ligation of the gene fragments into pEHISTEV 
and pLOU3 was carried out following standard protocol (Section I-5 to I-12, 
Figure 4.26) 
 
 
 
 
 
Figure 4.26 Agarose gel electrophoresis of construct-4 (hkrd region) 
(A) Amplification of vca0522_hkrd gene from genomic DNA of V. cholerae 
(using primer set 3). M, 1 kb DNA ladder (Promega); lane 1, amplification of 
vca0522_hkrd gene product. (B) Double digestion of clone positive plasmid 
selected by blue-white screening. Lane 1, double digested pEHISTEV vector 
and insert (vector 5 kb and insert 369 bp). 
In the expression trials, both the pEHISTEV and pLOU3 derived clones 
expressed the desired protein solubly, but for higher yields, the pEHISTEV 
clone was scaled up to five litres for purification. The protein was purified with 
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the same buffer used for Construct-3 protein purification (20 mM Tris-HCl pH 
7.4, 200 mM NaCl, 10-350 mM Imidazole). After two round of Ni2+- affinity 
column purification and one round of gel filtration chromatography, more than 
80% pure protein was obtained (Figure 4.27). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 Purification of HKRD (construct-4_6His) protein  
(A) First Ni2+- affinity column pull down. M, protein marker (Mark12™, 
Invitrogen); lane 1, cell lysate after IPTG induction; lane 2, supernatant after 
sonication; lane 3, flow-through (unbound protein) after loading sample on to 
the column; lane 4, column wash with the buffer containing 10 mM imidazole; 
lane 5-9, elution in buffer containing 350 mM imidazole. (B) TEV cleavage of 
his-tagged HKRD. Lane 2, TEV digested sample of HKRD. (C) Second Ni2+-
affinity column. Lane 1-3, HKRD without his-tag (D) Eluted HKRD after gel 
filtration chromatography. Lane 5-10, fractions containing HKRD protein. (E) 
Gel filtration chromatogram for HKRD. (F) Matched peptides of HKRD 
identified by mass spectrometry. 
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4.4.3 Crystallization of HKRD protein and crystal optimization 
After purification, a good yield of soluble protein was obtained and the protein 
was concentrated to 9.3 mg/ml. Two ml of pure protein was obtained, some of 
them was used for crystal trials and the rest was flash frozen using liquid 
nitrogen and stored at -80° C. For crystal trials, seven commercially available 
screens were used and the plates were set up using the robot “Honey bee” 
(Section IV-2).  
Two different protein concentrations were used in the initial screens; the 
higher concentration was 9mg/ml and the lower concentration was 5 mg/ml. 
After four weeks, an initial hit was obtained in the condition 33 of WIZARD I 
(Figure 4.28.A). The condition consisted of 0.1 M CAPS pH 10.5, 2.0 M 
(NH4)2SO4 and 0.2 M Li2SO4.  
For the optimization of the conditions, an optimization screen was used from 
Hampton research which accelerated the crystallization process fast enough 
to get a nice crystal (Figure 4.28.B) within one single day with the addition of 
0.1 M NDSB-256, a type of non-detergent sulfobetaine. One set of in-house 
data was collected from the optimized crystal (after cryo protecting it in 20% 
glycerol in crystallization solution).  
Several more crystals were soaked in heavy metals such that KAuCl4 from 1 
mM to 20 mM for several minutes to several weeks, and then excess heavy 
metal was washed out by rinsing the crystal in 2.5 M Li2SO4 (which also acted 
as a cryo protective agent) before mounting the crystal for data collection both 
in house and at the ESRF. 
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Figure 4.28 HKRD protein crystal and diffraction pattern 
 
(A) Initial hits in WIZARD-I screen number-33 (0.1M CAPS pH 10.5, 2.0 M 
(NH4) 2SO4 and 0.20 M Li2SO4). (B) Optimized crystal, using the initial hit 
condition, containing 9 mg/mL of protein and 0.1M of NDSB-256 (SIGMA) (C) 
X-ray diffraction image of the HKRD protein crystal. 
4.4.4 X-ray data processing  
For in house data collection the crystal was exposed to X-rays at 100K on the 
in-house Rigaku/MSC MicroMax-007HF rotating anode equipped with a 
Saturn 944+ CCD detector at wavelength 1.54178 Å. The crystal-to-detector 
distance, rotation angle and other parameters were initially set to measure a 
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2.7 Å resolution data set for preliminary analysis. For further comprehensive 
data collection, the detector was set at different distances based on the 
diffraction quality of the crystal. The first crystal of HKRD diffracted only at 
2.7 Å but after optimization, the crystal diffracted up to 2.5 Å. The 
crystallization data failed to be indexed and integrated using the program 
MOSFLM (Leslie 1992). After setting a distinct value of the box size to 25 and 
spot size to 0.20 it was possible to index, integrate and scale in DENZO 
program HKL2000 (Minor 1997). The crystal belongs to the group P321 with 
the unit cell parameters of a = b = 171.61 Å and c = 53.59 Å; α = β = 90.00, γ 
= 120.00 °. The scaled data was further converted and processed using the 
programs of the CCP4 suite (CCP4. 1994).  
4.4.5 Structure solution of HKRD  
Initial attempts to solve the structure by Molecular Replacement using the 
TrrA response regulator from Thermotoga maritima as the phasing model, 
with which HKRD shares 39% sequence identity (pdb accession code 3A0U), 
were unsuccessful. Calculation of the Matthews coefficient (Matthews 1968)	  
of 2.53 Å3/Da and 51.47 % solvent content suggested that possibly six 
molecules of HKRD were present in the asymmetric unit. However, a solution 
was only obtained when five molecules were searched for in the asymmetric 
unit, corresponding to a Matthews’s coefficient of 3.04 Å3/Da and 59.56 % 
solvent content. No extra electron density was observed for a sixth molecule. 
In addition, it was necessary to use an ensemble of five different 
superimposed models in PHASER: 3F6P (33% sequence identity to Vibrio 
cholerae HKRD), 1MVO (27%), 2A9R (27%), 3GWG (29%) and 3AOU (35%). 
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This latter molecular replacement step and partial refinement of the structure 
was performed by Dr Jane Potter. 
4.4.6 Structure of V. cholerae HKRD  
In the asymmetric unit, four of the molecules are arranged as two dimers and 
the fifth molecule forms a dimer with a crystallographically related chain. The 
R/Rfree values for the partially refined structure are 27.9% and 31.7% 
respectively (Figure 4.29) Details of the data sets are in Table 4.3. 
             
Figure 4.29 Structure of V. cholerae HKRD showing arrangement of the 
molecules in the unit cell in unit cell 
The five monomers present in the asymmetric unit are shown in green (chain 
A and E), blue (chain B and D), red (chain C). Chain C forms a dimer with its 
symmetry related monomer. 
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Table 4.3 X-ray data collection and refinement statistics 
A. Data collection In house  
X-ray wavelength (Å) 1.542 
Resolution (Å) 26.0 – 2.50 (2.57– 2.50) 
Unit cell parameter  
a, b and c (Å) 
α, β and γ (°) 
 
a=b=171.61, c=53.59  
α=β= 90.00, γ=120.00 ° 
Space group P 3 2 1 
No of unique reflections 5580 
Completeness (%) 99.6 (97.4) 
Redundancy 9.6 (6.5) 
Rmerge 0.065 (0.748) 
I/σI 45.46 (2.81) 
B. Data refinement  
Total number of atoms  4558 
Average B-factor (Å2) 
Protein, chain A/B/C/D/E 
 
29.10 
Rcryst 27.9% 
Rfree 31.7% 
rmsd from ideal 
Bond lengths (Å) 
Bond angles (º) 
 
0.019 
2.084 
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation 
of unique reflection h. 
bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh|, where Foh and F are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor, but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
 
The overall structure of V. cholerae HKRD is similar to the other common 
response regulatory protein structures solved so far, having a conventional 
doubly wound five stranded α/β motif except with an additional 310 helix 
between α-3 and β-4, designated as η-1 (Stock et al.,1989; Bent et al., 2004) 
(Figure 4.30, Figure 4.31, Figure 4.32). The central core region is formed by 
five β-sheets laying parallel to each other and is surrounded by five α-helices 
and the 310 helix. Helix α-1 and α-5 are located at one side of the central β-
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sheet core and the other helices (α-2, 3, 4 and 310 helix) are located at the 
opposite side (Figure 4.30, Figure 4.31, Figure 4.32). 
  
 
 
 
 
 
Figure 4.30 Superposition of HKRD monomer B  
HKRD (side view, coloured rainbow N-terminal to C-terminal) onto 3f6p (B. 
subtilis) in magenta, 1nxw (S. pneumoniae) in yellow and 3gwg (H. pylori) in 
cyan. 
 
 
 
 
 
 
Figure 4.31 HKRD monomer A (side view, coloured rainbow N-terminal to C-
terminal). 
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Figure 4.32 HKRD monomer A (top view, coloured rainbow N-terminal to C-
terminal). 
The interaction of five monomers to each other and to the symmetry mate is 
quite distinct from those shown in other related structures solved to date from 
the same group of proteins. Helix-3, helix-4 and loop β-3-to α-3 from both 
monomers interact for the dimer formation (Figure 4.33, Figure 4.34). The 
identical interaction is present between chain B and chain D, and between 
chain C and its symmetry related partner. 
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Figure 4.33 Interaction between chain A and chain E of HKRD 
Side view: (both of the chains are coloured rainbow N-terminal to C-terminal 
showing helix-3 in greenish yellow and helix-4 in brown) 
 
Figure 4.34 Interaction between chain A and chain E of HKRD 
Top view: (both of the chains are coloured rainbow N-terminal to C-terminal 
showing helix-3 in greenish yellow and helix-4 in brown) 
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Interaction between Chain D and chain E involves residues from Helix-4 from 
both of the chains (Figure 4.35, Figure 4.36).  
 
Figure 4.35 Interaction between chain D and chain E of HKRD 
Side view (both of the chains are coloured rainbow N-terminal to C-terminal 
showing helix-1 in shaded blue) 
 
 
 
 
 
 
 
Figure 4.36 Interaction between chain D and chain E of HKRD 
Side view-180 degree rotation (both of the chains are coloured rainbow N-
terminal to C-terminal showing helix-1 in shaded blue). 
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4.4.7 The active site of V. cholerae HKRD  
The active site region of V. cholerae HKRD has some conserved residues in 
common with homologous proteins from the same group of response 
regulators (Bent et al., 2004). Asp54, Ile55, Pro58, Gly61, and Gly36 are 
considered as the most important residues in the active site because of their 
role in catalytic activity and in maintaining the structural conformation of the 
active site (Figure 4.37). Asp54 is the site of phosphorylation, which receives 
the phosphate group from the upstream histidine kinase domain as a part of 
the signal transduction process (Henke and Bassler 2004b; Marina et al., 
2005). Asp54 is located in the cleft formed by loop-1 and loop-5, Ile55 and 
Pro58 from loop-5 can form hydrogen bond to Gly61 located in the helix α-3 
and Gly36 located in helix α-2. 
 
 
 
 
 
 
 
Figure 4.37 Stereo view of active site catalytic residues showing their 
positions in the molecule. 
The basic mode of HKRD activation is dependent on the binding of the 
corresponding signal molecule CAI-1 to the cell surface receptor region of 
CqsS, which is also dependent on the density of the bacterial population 
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(Figure 4.38). In the low cell density condition, the number of CAI-1 molecule 
synthesised by CqsA enzyme (chapter-2, 3) is considerably low and not 
enough to bind to the receptor region of CqsS. At this condition, CqsS acts as 
a kinase and the flow of phosphate goes to the conserved histidine residue 
located in the histidine kinase domain of CqsS. This causes the histidine 
kinase to go through a conformational change (Figure 4.38) and eventually 
transfers the phosphate group to the aspartic acid residue in the response 
regulatory receiver domain.  
 
 
 
 
 
 
 
 
Figure 4.38 Structure-based schematic of the reactions catalyzed by HK 
sensors 
The kinase auto phosphorylation (A-B), phosphotransferase (B-A*) and 
phosphatase (A*-A) activities are shown on projected outlines of the enzyme 
and protein–substrate models. Positions of N and C termini, ATP and the 
phospho-accepting histidine (H) are indicated on an HK dimer (orange and 
green). Position of phospho-accepting aspartate (D) is indicated on a RR 
(red). The transferred phosphoryl group is indicated as a yellow asterisk 
(Marina et al., 2005). 
The phosphate group is then transferred to the regulatory protein LuxO via 
phosphotransfer protein LuxU. Phosphorylated LuxO activates transcription of 
small RNAs called quorum regulatory RNAs that destabilize the master 
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regulatory protein HapR mRNAs. Because HapR blocks the transcription of 
virulence gene expression, when HapR is blocked the bacteria can produce 
all of its virulence gene products like cholera toxin and bio film (Marina et al., 
2005; Hammer and Bassler 2007). 
In high population density, binding of the CAI-1 to the cell surface receptor 
region of CqsS causes the flow of phosphate to occur in the opposite direction 
due to reversion of the conformational change of its domains (Figure 4.38) 
leading to eventual repression of the virulence gene expression (Figure 4.39) 
(Marina et al., 2005; Hammer and Bassler 2007).  
 
 
 
 
 
 
 
Figure 4.39 Model of V. cholerae quorum-sensing systems 
V. cholerae possesses the CAI-1–CqsS system and the AI-2–LuxPQ system. 
V. cholerae also has an unidentified third circuit (System 3) that acts through 
LuxO. Phosphate flows toward LuxO at low cell density, and the flow of 
phosphate is reversed at high cell density (double-headed arrows). 
Abbreviations: H, histidine; D, aspartate; HTH, helix-turn-helix; IM, inner 
membrane; OM, outer membrane (Henke and Bassler 2004a). 
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4.4.8 Comparison of V. cholerae HKRD with previously solved response 
regulatory enzyme structures 
V. cholerae HKRD displays a high degree of similarity to its homologous 
proteins. The closest homologues are the receiver domain YYCF from B. 
subtilis pdb code 2zwm (rmsd 1.24 Å over 120 Cα atoms) and 3f6p (rmsd 
1.27 Å over 120 Cα atoms). Superposition of the V. cholerae HKRD structure 
over its homologous protein structures revealed that the V. cholerae HKRD 
structure is similar to the other structures solved to date with some variability 
in the loop size and the length of the two terminal β-strands (β-4 and β-5). 
Another exception was the presence of a 310 helix (η-1) in the V. cholerae 
HKRD structure between α-3 and β-4, which is absent in all of its structural 
homologues (Figure 4.40). Sequence alignment of the protein with its 
structural homologues (Figure 4.4.13) also shows the similar conserved 
residues in the entire structure and in the catalytic site. It can be concluded 
that the structural study on this protein was successful and further additional 
catalytic activity experiments could be done in the future (detailed of the future 
experiment plan is described in chapter-7).  
 
 
 
Figure 4.40 Sequence alignment of V. cholerae HKRD with its structural 
homologues. 
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Chapter 5 
Structure determination and functional analysis of Vibrio cholerae aldo-
keto reductase enzyme (VCA0859) 
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5. Structure determination and functional analysis of Vibrio cholerae 
Aldo-keto reductase enzyme (VCA0859) 
5.1 Target protein 
Our studies on CqsA predicted the formation of diketo-CAI-1 and it was 
speculated that an aldo-keto reductase enzyme is necessary to convert the 
doketo-CAI-1 into the final CAI-1. After searching for a keto reductase enzyme 
in V. cholerae, VCA0859 was picked as it was the only keto reductase 
annotated in the V. cholerae genome. 
VCA0859 protein belongs to the family of enzymes called aldo-keto reductase 
(AKR). AKRs constitute a group of diverse cytosolic enzymes that can 
catalyze the reduction of a variety of substrates like aldehydes, steroids, 
aldoses or even simple monosaccharides in the presence of their co-factor 
nicotinamide adenine dinucleotide phosphate [NAD(P)H] (Jeudy et al., 2006). 
The AKR family is represented in most living cells as monomeric (α/β) 8-barrel 
proteins of about 300 amino acids in length. All the members with an (α/β) 8-
barrel have a common catalytic tetrad composed of a tyrosine, a lysine, an 
aspartate, and a histidine. Despite all these common properties, members of 
the AKR family often exhibit very little sequence similarity. It has been 
proposed that the length and sequence of several highly variable loops in their 
three dimensional (3D) structures are responsible for the difference in 
substrate specificity exhibited by AKR family members. (Jez et al., 1997) 
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5.1.1 Overview of VCA0859  
The VCA0859 protein of V. cholerae O1 El Tor strain N16961 is an 
oxidoreductase enzyme, (aldo/keto reductase family) that contains 307 amino 
acid residues. The molecular weight of VCA0859 is 34.72 kDa and its 
calculated isoelectric point (pI) is 6.18. Sequence analyses of this protein in 
the bioinformatics server Phyre (Kelley et al., 2009) suggested that the protein 
is an NADPH dependent aldo-keto reductase and its homologous proteins 
form a TIM alpha/beta-barrel. A RONN (Yang et al., 2005) analysis showed 
the first 19 residues and residue no 272-281 predicted to be disordered. 
 
 
 
 
 
 
 
 
 
Figure 5.1 VCA0859 disorder prediction by RONN 
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5.2 Cloning, protein expression, purification and crystallization 
5.2.1 Vectors 
A modified pEHISTEV vector (Liu and Naismith 2009) (section I-3, Fig I-1.A) 
named (pHis_lacZα) (Dr Md. Arif Sheikh : personal communication) was used. 
This modified vector has a lacZ gene downstream of the multiple cloning sites 
that facilitate screening of the positive colonies by blue-white screening 
(section I-10.A). 
5.2.2 Gene amplification, restriction digestion, ligation and positive 
clone identification 
Amplification of the vca0859 gene was carried out by PCR from genomic DNA 
of V. cholerae O1 El Tor strain N16961 using standard protocols (Section I-5) 
(Figure 5.2.A). Primers (VHBIO, UK) for PCR amplification from genomic DNA 
contained specific recognition sites EcoRI in the forward primer (5ʹ′- 
GGCATGAATTCATGCAACAACAAGCAACCGTACAG -3ʹ′) and XhoI site in 
the reverse primer (5ʹ′- GTTATCTCGAGTTATGGCACGCCATGACCTTG -3ʹ′). 
After amplification, the PCR product was digested with the respective 
enzymes and cloned into the similarly digested expression vector 
(pEHISTEV_lacz∝) (Section I-3. A), (Figure I-1. A). After propagation in E. coli 
DH5α strain, the positive clones were picked up by blue/white screening 
(section I-10. A), Figure I-2), due to the presence of lacZα complementation 
gene in pEHISTEV_lacz∝ vector. Positive clones were verified by double 
digestion (Figure 5.2.B), (Section I-7) and DNA sequencing (Section I-11). 
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Figure 5.2 Agarose gel electrophoresis of vca0859 gene products 
(A) Amplification of vca0859 gene from genomic DNA of V. cholerae O1 El 
Tor strain N16961. M, 1 kb DNA ladder (Promega); lane 1, Amplification of 
VCA0859 gene products. (B) Double digestion of cloning vector 
pEHISTEV_lacz∝ containing VCA0859 gene. Lane 1 (bottom band), insert 
vca0859 gene fragment; lane 1 (top band), linear vector without insert gene 
after double digestion. 
5.2.3 Protein over expression and purification 
The gene vca0859 cloned into pEHISTEV vector was transformed into 
expression host E. coli BL-21 (DE3). In the expression trial, good soluble 
protein expression was observed at 25 °C overnight expression in the 
presence of 1 mM IPTG (section II-1) (Figure 5.3.A). Protein identity was also 
confirmed by mass spec (section III-1).  The expression trial was then scaled 
up to five litres of culture and the protein purified using standard method 
described earlier  (Section III-2, Figure 5.3) using purification buffer (PBS plus 
300mM NaCl, 10-350 mM Imidazole). After two rounds of Ni2+_ column 
purification followed by a gel filtration chromatography (sectionIII-2.4) (Figure 
5.3.E, F) more than 80% pure protein was obtained.  
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Figure 5.3 Purification of VCA0859 
 (A) Lane 1, Whole cell sample at 37 °C after 3 hours of incubation; lane 
2,soluble sample at 37 °C after 3 hours of incubation; M, protein marker 
(Mark12™, Invitrogen); lane 3, Whole cell sample at 25 °C after overnight of 
incubation; lane 4, soluble sample at 25 °C after overnight of incubation. (B) 
First Ni2+-affinity column purification. Lane 1, cell lysate after sonication; lane 
2, supernatant after sonication; lane 3, flow-through (unbound protein) after 
loading sample on to the column; M, protein marker (Mark12™, Invitrogen); 
lane 4-5, column wash with the buffer containing 20 mM imidazole; lane 6-9, 
elution in buffer containing 250 mM imidazole. (C) TEV cleavage of his-tagged 
VCA0859. Lane 1, TEV undigested sample of VCA0859; lane 2, TEV digested 
sample of VCA0859. (D) Second Ni2+-affinity column. Lane 1, before loading 
sample on to the column; lane 2, flow-through (unbound protein) after loading 
sample on to the column; M, protein marker (Mark12™, Invitrogen); lane 3-4, 
column wash with the buffer containing 20 mM imidazole; lane 5, elution in 
buffer containing 50 mM imidazole. (E) Lane 1, before loading sample on to 
the gel filtration column; M, protein marker (Mark12™, Invitrogen); Lane 2-9, 
fractions containing VCA0859 protein eluted after gel filtration 
chromatography. (F) Gel filtration chromatogram for VCA0859. (G) Matched 
peptides of VCA0859 identified by mass spectrometry. 
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5.2.4 Pre-crystallisation test 
The protein samples were concentrated to 8.5 mg/ml using a 10,000-Da 
MWCO centrifugal concentrator (Milipore). Two ml of pure protein was 
obtained, small aliquots of 50 µl of the protein sample were flash frozen in 
liquid nitrogen and stored at -80 °C. The PCT™ (Pre-Crystallization Test from 
Hampton Research) was used to determine the appropriate protein 
concentration for crystallization screening (section IV-1). The ideal 
concentration to crystallize the VCA0859 protein was determined to be 8.5 
mg/ml.  
5.2.5 Protein crystallization and optimization 
A total of seven crystal screens were set-up with two different protein 
concentrations, which were 8.5 mg/ml and 6.8 mg/ml. A total of seven 
different commercially available crystallization screens were used to screen 
initial conditions of crystallization (section IV-2). Crystal plates were initially 
setup using the Honeybee crystallization robot (Genomic Solutions) in the 
SSPF (www.sspf.ac.uk) with 150 nl of buffer and 150 nl of protein (section IV-
2). An initial hit was obtained in Wizard (I+II) plate, well No 12D. The crystal 
condition was: 100mM acetate (pH 4.5), 20% PEG 1000 (w/v) and 200 mM of 
Zn- acetate. The crystals grew within three days in a shape of a needle 
cluster, but when checked in the X-ray machine, there was no diffraction at all. 
Several rounds of optimization and X-ray shooting proved that the crystal was 
indeed a salt crystal, which is quite common with using a phosphate buffer. 
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5.2.6 Thermal shift assay 
For both structural studies and functional assays, a more stable protein is 
necessary. Many proteins are unstable under standard buffer conditions, 
while others are stable in many buffer conditions. Protein solubility, stability 
and homogeneity are some very important factors that are related to the 
development of a protein crystal. In a protein crystallization experiment, the 
solvent environment plays a very critical role in every step that eventually 
leads to the growth of the crystal (Ericsson et al., 2006).The selection of the 
buffer is therefore very important. 
A thermal shift stability-based high-throughput stability optimization screen 
was performed using four different buffers of several different pH values as 
shown in Table 5.1.The assay was performed in a 96-well thin-walled PCR 
plate (Bio-Rad). The reaction mixture contained 5 µl of protein (2.5 mg/ml), 
2.5 µl of Sypro® orange (50X) and 42.5 µl of buffer. The plate was then 
sealed with Optical Quality Sealing Tape (Bio-Rad) and heated in a Mx3005P 
QPCR system from 25 to 95 °C with a gradual increase in temperature of 
0.5 °C per cycle. A CCD (charged-coupled) camera is attached with the 
machine that records any changes in the excitation and emission (at 490 and 
575 nm respectively) in the samples to be tested (Ericsson et al., 2006). 
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Table 5.1 Buffer screens used for thermal shift assay 
Buffer pH 
50 mM sodium citrate + 50 mM NaCl + 5% glycerol pH 5.5 
50 mM sodium citrate + 50 mM NaCl + 5% glycerol pH 6.2 
50 mM sodium phosphate + 50 mM NaCl + 5% glycerol pH 6.5 
50 mM sodium phosphate + 50 mM NaCl + 5% glycerol pH 7.5 
50 mM potassium phosphate + 50 mM NaCl + 5% glycerol pH 6.5 
50 mM potassium phosphate + 50 mM NaCl + 5% glycerol pH 7.5 
50 mM HEPES + 50 mM NaCl + 5% glycerol pH 6.5 
50 mM HEPES + 50 mM NaCl + 5% glycerol pH 7.5 
 
The method is based on the changes in the fluorescence spectra of the dye 
sypro® orange in different chemical environments. This dye shows low 
fluorescence in aqueous solutions but higher fluorescence in non-polar 
environments such as the hydrophobic pockets of proteins.  
With the increasing temperature when the protein starts to unfold and 
hydrophobic regions become exposed, sypro® orange binds to the exposed 
hydrophobic regions of the protein and results in a significant increase in 
fluorescence emission. The emission continues to increase up to a maximum 
level and then starts to decrease due to the denaturation of the 
protein(Ericsson et al., 2006). The graph (Figure 5.5) shows experimental 
results of thermal shift assay of VCA0859 with different buffer. 
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Figure 5.5 Buffers screening of VCA0859 by thermal shift assay 
5.2.7 Buffer change 
The result of the thermal shift assay (Figure 5.5) clearly indicated that buffer B 
(50 mM sodium citrate + 50 mM NaCl + 5% glycerol, pH 6.2) was a better 
buffer for the protein VCA0859. Several aliquots of frozen protein were 
removed from the -80 °C freezers and dialyzed into this buffer with and 
without addition of 100 µM of NADPH (nicotinamide adenine dinucleotide 
phosphate) (Sigma). The two dialyzed protein samples were then used to set 
up crystallization plates using the Honeybee robot (Genomic Solutions).  
5.2.8 Protein crystallization and crystal optimization 
After a buffer change from PBS to citrate buffer, a nice crystal was found in 
the condition Index D4 after seven days with the protein concentration of 8.5 
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mg/ml. The crystal was about 0.5mm X 0.2 mm X 0.2. The crystallization 
solution contained: 0.1M citric acid pH 3.5 and 25% (w/v) PEG 3350 as 
precipitant. Initial crystal had some cracks in it due to the presence of several 
layers (Figure 5.6.A). Further optimizations were carried out by varying the 
concentration of protein, PEG, and pH of the buffer. The best quality crystals 
grew in 35% (w/v) PEG 3350 and 0.1M citric acid pH 4.0, using 6.8 mg/ml 
protein (Figure 5.6.B). 
5.2.9: X-ray data collection and processing  
A suitable protein crystal was picked out from the drops with a crystal loop 
and transferred to 5µl of cryoprotectant drop (crystallization buffer with 10% 
glycerol and 10% ethylene glycol). The crystal was then re-looped and 
exposed to X-rays at 100K on the in-house Rigaku/MSC MicroMax-007HF 
rotating anode equipped with a Saturn 944+ CCD detector at wavelength 
1.54178 Å. The crystal-to-detector distance, rotation angle and other 
parameters were initially set to measure a 2.7 Å resolution data set for 
preliminary analysis. For further comprehensive data collection, the detector 
was set at different distances based on the diffraction quality of the crystal. 
The first crystal of VCA0859 diffracted only at 2.9 Å but after optimization, the 
crystal diffracted up to 2.2 Å. The crystallization data were indexed and 
integrated using the program MOSFLM (Leslie 1992). The integrated data 
were merged and scaled using the programs of the CCP4 suite (CCP4. 1994). 
The crystal belongs to the group primitive orthorhombic (P212 21) with the unit 
cell parameters a=79.79 Å, b=88.55 Å and c=138.81 Å; α=β=γ=90°. 
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Figure 5.6 VCA0859 protein crystal and diffraction pattern 
(A) Initial hits in INDEX screen (well number D4; 0.1M citric acid pH 3.5 and 
25% (w/v) PEG 3350). (B) Optimized crystal, containing 6.8 mg/mL of protein 
and 0.1 M citric acid pH 4.0 and 35% (w/v) PEG 3350. (C) X-ray diffraction 
image of VCA0859 protein crystal, crystal to detector distance of 70 mm. 
5.2.10 Crystal soaking experiment 
Dialysis of the protein in the presence of 100 µM NADPH containing buffer 
prior to crystallization, did not give a complete NADPH electron density in the 
active site of the crystal structure. Only discrete blobs of electron density that 
could accommodate adenosine and phosphate were found. To obtain a full 
NADPH bound enzyme structure some soaking experiments were done. 4 µl 
of crystallization solution containing 10mM of NADPH was added to the 4 µl of 
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crystallization drop containing VCA0859 crystals, which made a final 
concentration of 5mM NADPH. The crystal-soaking drop was sealed with a 
crystal clear tape and incubated at room temperature for 90 minutes. The 
crystal was then cryo protected using the same method as the native crystal 
and a set of data containing 360 images were collected at a resolution about 
2.1 Å. A prolonged soaking over three days was also tested but it cracked the 
crystal. Crystals were also soaked in the presence of NADPH (5 mM) and 
either of the compounds: compound-1, compound-2 and compound-8 (5 mM 
each) (Figure 5.7).  Data from compound-1 soaking was process able and 
structure was solved eventually but the crystals soaked with compound-2 and 
compound-8 did not diffract well and it was not possible to collect any 
process- able data sets with those crystals.  
 
Figure 5.7 Compounds used in the crystal soaking experiment 
Compound 1 was synthesized by Dr. Magali Lorion (Dr. N.J. Westwood 
group, University of St Andrews). Compound 2 was Synthesized by 
Synthesized by Dr. Ravi Pathak (Dr. N.J. Westwood group, University of St 
Andrews). Compound -8 was purchased from Sigma. 
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5.2.11 Structure solution and refinement 
The initial phase for the apo structure was determined with the software 
PHASER (McCoy et al., 2007) using the trimer model of Ydhf, an aldo-keto 
reductase from Escherichia coli (pdb model 1OG6) (58% sequence identity 
with VCA0859) as the molecular replacement model. The initial phase was 
then read in Coot (Emsley and Cowtan 2004) to build the entire trimer chains 
A , B and C. The structure was then further refined using REFMAC 
(Murshudov et al., 1997) to R factor and the R free values of 27% and 40% 
respectively. An attempt to produce holo enzyme crystals by co-crystallization 
in the presence 100 µM of NADPH was not completely successful; density for 
only the phosphate groups of the NADPH was detected in the NADPH co-
crystals. Crystals were soaked in NADPH (5 mM) and in the presence of 
NADPH and compound-1, 5mM each. The latter structures were solved by 
molecular replacement using the apo structure of VCA0859 as a model. 
Interestingly, after optimization the protein was crystallized in primitive 
monoclinic (P21) space group rather than primitive orthorhombic (P212 21) and 
the unit cell parameters (a, b, c; α, β, γ) also changed.  
5.2.12 Statistics for X-ray data collection and processing of VCA0859 
holo crystals 
All X-ray data sets for the VCA0859 holo forms (with NADPH) were collected 
on the in-house Rigaku/MSC MicroMac-007HF rotating anode X- ray 
generator equipped with VariMax optics and a Saturn 944+ CCD detector. 
Details of the data sets are in Table 5.2. 
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Table 5.2 X-ray data collection and refinement statistics 
 
aRmerge = ∑h∑ j| Ihj- 〈Ih〉|/∑h∑ j, where Ihj is the intensity of the jth observation 
of unique reflection h. 
Data set Apo 
 
Holo  
(NADPH 
Soaked) 
Holo  
(NADPH + 
Comp1 
soaked) 
A. Data collection    
Resolution (Å) 20.42 – 2.22 
(2.28– 2.22) 
15.42 – 2.20 
(2.25 – 2.20) 
21.54- 2.65 
(2.65-2.65) 
Unit cell (Å) 
a 
b 
c 
 
88.56 
79.86 
138.15 
 
80.30 
138.78 
88.77 
 
80.15  
88.50   
138.71 
α 
β 
γ 
90.00  
90.39    
90.00 
90.00  
90.21    
90.00 
90.00  
 90.00  
 90.00 
Space group P21  P21 P212 21 
X-ray source In-house In-house In-house 
Wavelength (Å) 1.542 1.542 1.542 
No. of unique 
reflections 
 
90852 
 
74060 
 
29232 
Completeness (%) 95.3 (88.9) 75.2(70.4) 99.8(99.8) 
Redundancy 3.1(2.6) 2.0 (2.2) 6.3 (4.8) 
aRmerge 0.075(0.346) 0.114(0.361) 0.170(0.742) 
I/σI 24(4.3) 4.7 (2.1) 10.3(2.1) 
B. Data refinement    
Number of atoms 
Protein 
Ligand 
 
Water 
 
14394 
0 
 
0 
 
4448 
282 
(6 NADPH) 
412 
 
7224 
141 
(3 NADPH) 
0 
Average B-factor 
(Å2) 
Protein, chain 
A/B/C/D/E/F or 
A/B/C 
Ligand 
Water 
 
 
32.48 
 
 
- 
- 
 
 
20.37 
 
 
26.112 
19.75 
 
 
27.858 
 
 
46.751 
- 
Rcrystb 
Rfreec 
25.87% 
32.47% 
24.19% 
30.76% 
22.94% 
29.68% 
rmsd from ideal 
Bond lengths (Å) 
Bond angles (º) 
 
0.017 
1.62 
 
0.008 
1.18 
 
0.013 
1.658 
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bOverall R factor ∑h||Foh| - |Fch||/∑h|Foh|, where Foh and F are the observed and 
calculated structure factor amplitudes for reflection h. 
cFree R factor is equivalent to overall R factor, but is calculated using 5% of 
reflections excluded from the maximum-likelihood refinement stages. 
 
5.2.13 Structure of VCA0859 
There are two trimers of the holo-VCA0859 molecule in the P21 crystal form, 
solvent content 47.7 %, Matthew's coefficient 2.35. The VCA0859 structure is 
similar to the other members of the aldo-keto reductase family. This enzyme 
also has the typical (α/β) 8-barrel structure. The (α/β) 8-barrel (TIM barrel) 
motif is formed by the compact packing of eight β-strands (β3-5, β8-12) that 
makes a cylindrical core, which is surrounded by eight α-helices (α1, α3-7, 
α10-11). The α-helices are coiled in an antiparallel direction relative to the β-
strands that form the core structure of the TIM barrel. 
There are four extra helices (symbolized as α2, α8, α9, α12) and four 310 
helices (symbolized as η1-4) that interrupt the basic TIM barrel structure. The 
extra helices are located at the C-terminal end of the protein (Figure 5.8. A 
and C). Although the eight β-strands form the basic cylindrical core structure 
for the barrel, the first two β-strands at the N-terminal are packed in a hair-pin 
like pattern that forms a cap like structure at the bottom of the barrel to give 
the barrel a funnel like shape. The closest structural homologues to VCA0859 
are the AKRs from Mycobacterium smegmatis (rmsd 2.21 Å over 250 Cα s) 
and Bacillus halodurans (rmsd 2.18 Å over 264 Cα s). 
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5.2.14 NADPH-binding pocket 
The co-factor NADPH binds to the enzyme such that the nicotinamide ring is 
buried the deep inside of the barrel cavity whereas the adenosine phosphate 
extends out to the rim. Four residues in the catalytic site are particularly 
important for their role in substrate reduction and are highly conserved, 
forming a catalytic tetrad, designated as DxxxxY, K and H (Jez et. al.,1997; 
Scoble et. al., 2010). The catalytic tetrad for this enzyme has been identified 
as D55, Y60, K88 and H135 by sequence alignment with other homologous 
enzymes from different bacteria: E. coli (59% sequence identity), Bacillus 
subtilis (27%), Bacillus halodurans (21%) and Mycobacterium smegmatis 
(23%) (Figure 5.9). The basic mechanism of reduction by this family of 
enzymes involves the transfer of a proton from the enzyme and a hydride 
from the cofactor NADPH to its substrate. For this reason, the catalytic tetrad 
and some additional residues in the active site that are involved in NADPH 
binding are highly conserved. During the substrate reduction process, the Tyr 
(usually) acts as the proton donor; the de-protonation is facilitated by a 
charged hydrogen bond that was formed between the Tyr and the catalytic 
Lys. The same Lys also forms a salt bridge with the catalytic Asp. The 
catalytic His can play the role of a proton donor in some Akrs (Scoble et. al., 
2010). Like the 2wzm structure from Mycobacterium smegmatis, the catalytic 
tetrad of VCA0859 is located at the rim of the barrel, which is the most 
common position for any member of AKR family (Figure 5.8. D).  
In the holo enzyme structure obtained by NADPH soaking electron density 
was observed for the whole chain of NADPH and it was possible to compare 
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the structure with the holo enzyme structure of other proteins of the same 
family (Figure 5.7). The adenosine ring of the NADPH is bound to the enzyme 
in the α11 helix by making H-bond with the Ser280 and Ala 281.  
There are also some van der Waals (vdw) contacts existing between the 
adenosine ring and the side chain of some additional residues: Leu219, 
Ile224, Ser250, Ile251, Ser272, Arg277 and also to the main chain of Gly271 
(as seen in Mycobacteria smegmatis enzyme, 2wzm) (Scoble et. al., 2010). 
 
Figure 5.8.A Trimer structure of holo VCA0859 
Each monomer is drawn in rainbow colours from blue at the N-terminus to red 
at the C-terminus. The NADPH present in each active site is drawn in space 
filling mode and coloured by element.  
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Figure 5.8.B Stereo view of the holo VCA0859 structure alignment 
VCA0859 (in green), 2wzm (in cyan) from Mycobacteria smegmatis and 1ynp 
(in yellow) from Bacillus halodurans (N-terminal and C-terminal has been 
marked as blue and red spheres respectively). (NADPH has been shown as 
space filling mode). 
 
 
 
 
 
Figure 5.8.C Side view of structure alignment of VCA0859 
VCA0859 (in green), 2wzm (in cyan) from Mycobacteria smegmatis and 1ynp 
(in yellow) from Bacillus halodurans (N-terminal and C-terminal has been 
marked as blue and red spheres respectively). (NADPH has been shown as 
space filling mode). 
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Figure 5.8.D Monomer of holo VCA0859 showing NADPH and catalytic tetrad 
C-terminus is shown as red sphere and NADOH is shown as space filling 
mode and coloured by element. 
 
Figure 5.8.E Closer view of the active site showing catalytic tetrad 
NADPH and residues of the catalytic tetrad in the active site are coloured by 
element. 
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After soaking the enzyme crystal in the presence of NADPH and compound-1, 
better density was observed that could accommodate the whole chain of 
NADPH and some extra electron density was also observed in the active site 
(of all of the three chains) that is very close to the nicotinamide ring. 
Unfortunately it was not long enough to accommodate the whole chain of 
azidoheptanoyl-CoA. It has not been possible so far to confirm if this extra 
density appeared because of the presence of any enzymatic reaction product 
or it picked some compound from the crystallization solution (Figure 5.7.G).  
5.2.15 Sequence similarity of VCA0859 to that of other AKRs 
In order to understand the structural and functional significance of VCA0859, 
the amino acid sequence and the structure of the protein was submitted to 
various bio-informatics servers such as: RONN (Yang et al., 2005) PHYRE 
(Kelley et al., 2009), BLAST (Altschul et al., 1990) and PDBe (S. Velankar 
2010). The servers compared the sequence and the structure with all the 
sequences and structures so far available online and compared those of 
VCA0859 to those of its orthologues and homologues from the closely related 
bacterial species. When the sequence of the protein was aligned with its 
closest homologues from other bacteria using ClustalW (Chenna et al., 2003) 
and the structural element alignment using ESPRIPT (Gouet et al., 2003) it 
was predicted that the structure of VCA0859 shares the same overall folding 
pattern as its closest structural homologues (Figure 5.8).  
All of them have a (α/β) 8-barrel (TIM barrel) motif, catalytic tetrad, designated 
as DxxxxY, K and H and some conserved and highly conserved residues that 
make contact with the co-factor, NADPH and play important roles in substrate 
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recognition and subsequent reduction (Figure 5.9). Most of the enzymes from 
this family studied so far with a published structure have been shown to have 
an aromatic residue at position 30 (W, Y or F, in 84 % of enzymes compared 
in an earlier study (Scoble et. al., 2010), whereas VCA0859 has an alanine 
and its closest structural homologue 2wzm from M. smegmatis, has a glycine 
in this position. This position is particularly important because it lines up one 
side of the nicotinamide ring of the NADPH and the presence of an aromatic 
residue at this position in the enzyme is more likely to constrain the 
nicotinamide ring in its proR conformation and makes it less likely to form its 
other stereo isomer proS. Like the 2wzm structure, in VCA0859 both of the 
stereoisomer of NADPH can contact Tyr60 of the catalytic tetrad.  
 
Figure 5.8.F VCA0859 showing NADPH, A30 and catalytic tetrad in the active 
site 
D55, Y60, K88, H135 and A30; labelled and shown in stick model. 2Fo-Fc 
map shown for NADPH in purple. 
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Figure 5.8.G Stereo view of VCA0859 active site showing NADPH and extra 
electron density appeared as blobs.  
Fo-Fc map shown in purple and contoured at 3σ. 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 The structure-based sequence alignment of AKR Family members 
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5.2.16 Enzyme assay (reductive assay) 
The reductive assay was carried out in a Cary 50 UV-Vis spectrophotometer 
(Varian). Using a 1ml quartz cuvette containing varying concentrations of 
enzyme (0-5 µM) and varying concentrations of substrates (0-5mM) in 20mM 
potassium phosphate (pH 7.5), 200mM NaCl and a constant concentration of 
0.15 mM NADPH (Chang et al., 2007), (Jeudy et al., 2006). Corresponding 
control samples contained all other components except the enzyme. After 
addition of the substrate, the reactants were mixed well and incubated at 25 
°C for 30 seconds and their absorbance was recorded in the 
spectrophotometer. A baseline was also calculated using buffer only.  
5.2.17 Substrate specificity and catalytic properties of VCA0859 
Members of AKRs family are known to catalyze the reduction of aldehydes, 
aldoses, dicarbonyls, steroids, and monosaccharides in the presence of their 
co-factor NADPH. To determine the substrate preference of VCA0859, and if 
it can catalyze the reduction of α-amino ketone (Chapter-2, Figure 2.1, 4a) 
intermediate product produced by the enzyme CqsA as described in chapter-
2, its activity was tested against two synthetic compounds (compound-1 and 
compound-2) and six more commercially available aldehydes (AKR 
substrates, compound-3 to compound-8) and D-glucose (Jeudy et al., 2006).  
The enzyme seemed to be active in the presence of NADPH and can reduce 
compound-1 (azidoheptanoyl-CoA), although the rate of the reaction is not 
significant. There was very poor activity against compound-2 (di-keto 
substrate). There was no activity against aromatic ring containing substrate 
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compound-4 (benzaldehyde) and it seemed to precipitate the protein. 
Compound-5 (ethyl 2-methyl aceto acetate) also precipitated the protein. 
Compound-3, compound-8 and glucose showed no significant activity with the 
protein although they did not precipitated the protein either (Table 5.3 and 
Figure 5.10). The same results were found with compound-6 and 7 as well 
(data not shown).  
Although the structural determination of VCA0859 was successful, it was not 
possible to identify the potential substrates of the enzyme. The soul purpose 
of studying this enzyme was to find out if it could catalyze the final step of 
reaction in CAI-1 biosynthesis by reduction of diketo-CAI-1 (produced by 
CqsA).  
As it did not show any remarkable activity with the synthetic diketo-CAI-1, 
called compound-2 in this study, it can be concluded that this enzyme is not 
the proper keto reductase for this purpose and identification of the potential 
substrates for this enzyme needs to be carried out. However in a recent paper 
(Wei et al., 2011) has reported the activity of another keto reductase VC1059 
from V. cholerae to perform the reaction in vitro. 
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Table 5.3 Reduction assay of VCA0859 in the presence of NADPH 
Time Comp1 Comp2 Comp3 Comp8 Glucose 
0 1.2201 1.1421 0.9951 0.9515 0.6192 
1 1.2049 1.1393 0.9922 0.9401 0.6185 
2 1.1786 1.137 0.9891 0.9292 0.6167 
3 1.157 1.1352 0.98551 0.9179 0.6155 
4 1.138 1.1334 0.98275 0.9064 0.6152 
5 1.1194 1.1317 0.97922 0.896 0.6137 
Slope (Ab/min) 0.02 0.002 0.0032 0.011 0.0011 
 
Assay with Aldehydes (2mM each) 
 
Figure 5.10 Assay with Aldehydes (2mM each) 
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Figure 5.11 Compounds used for the assay 
Compound 1 was synthesized by Dr. Magali Lorion (Dr. N.J. Westwood 
group, University of St Andrews). Compound 2 was Synthesized by 
Synthesized by Dr. Ravi Pathak (Dr. N.J. Westwood group, University of St 
Andrews). Compound 3-8 was purchased from Sigma.
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6. Cloning, expression and purification of VCA0939 protein 
6.1 Overview of VCA0939 Protein  
VCA0939 is an Auto-inducer repressed gene (vca0939) product that has a 
conserved GGDEF domain and is believed to be particularly important for its 
ability to synthesize cyclic di-GMP. Cyclic di-GMP is a small cycle of RNA, 
consisting of two-guanine bases with a ribose sugar and a Phosphodiester 
backbone (Figure 6.1). This small molecule is considered as a second 
messenger, which regulates various cellular processes in the quorum sensing 
of V. cholerae, including biofilm formation (Hammer and Bassler 2007). 
 
 
 
 
 
 
 
Figure 6.1 Cyclic di-GMP 
This protein, VCA0939 has been proven to control quorum sensing in a 
manner that does not require the functional master regulator HapR because 
of its ability to synthesize second messenger cyclic-di-GMP, which can base 
pair with another vital component of the QS-circuit, Qrr sRNAs. This type of 
QS-regulation is known as HapR independent quorum sensing (Chapter-1, 
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Figure 1.8, pathway-B) (Hammer and Bassler 2007). Recent analysis of the 
genome sequence of all known Vibrio species revealed that the V. cholerae El 
Tor strain N16961, known as V. choleraeEl, (responsible for the seventh 
pandemic cholera) and V. cholerae classical strain (responsible for sixth 
cholera pandemic) known as V. choleraeCl, strain 0395 were found to have a 
nonsense mutation in their HapR gene (hapR). A HapR independent mode of 
QS has been found in these strains where GGDEF containing proteins, 
including VCA0939 have been found to control the QS process (Hammer and 
Bassler 2007) (Chapter-1, Figure 1.8, pathway-B and Figure 6.2). 
 
 
 
 
 
 
 
Figure 6.2 Multiple regulatory pathways control biofilm formation in V. 
cholerae 
(A) In V. choleraeEl, sensory inputs from two QS AIs, CAI-1 (squares) and AI-
2 (circles), regulate HapR, which in turn modulates the levels of c-di-GMP, 
vps transcription, biofilm formation, and virulence. (B) In V. choleraeCl, the Vie 
SAB sensory system, in response to an unknown signal (triangles), controls c-
di-GMP levels to control vps transcription, biofilm formation, and virulence in a 
HapR-independent manner (Hammer and Bassler 2007). 
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 In V. choleraeEl strains, deletion of cqsA and !luxS gene does not prevent the 
expression of the vca0939 gene but addition of exogenous AI causes about 
30 fold reduction of vca0939 gene expression (Figure 6.3) (Hammer and 
Bassler 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 HapR-independent expression of vca0939 
vca0939-lux expression in V. choleraeEl strains incubated in a 1:1 co-culture 
with either a V. cholerae El Tor CAI-1-", AI-2-" strain (AIs, open bars) or a V. 
cholerae El Tor CAI-1+#, AI-2+# strain (AIs, filled bars) and V. choleraeEl 
monocultures (Hammer and Bassler 2007). 
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6.2 Regulation of gene expression by vca0939 in V. cholerae El Tor  
In the El Tor strain (V. cholerae), the QS regulation is controlled in a HapR- 
independent manner where Qrr1 directly regulates the expression of the 
vca0939 gene. Hammer et al., used the MFOLD algorithm to predict the 
secondary structure of Qrr/hapR and Qrr/vca0939 mRNA hybrids. (Figure 
6.4). The base pairing of Qrr/vca0939 was identical to that of Qrr/hapR. The 
algorithm also predicted the exact base-pairing of Qrr/vca0939 with each of 
the four Qrr sRNAs and the critical base pairing region in each of the sRNA 
was shown to be identical as observed in Qrr/hapR base pairing. The 
ribosome-binding site of vca0939 mRNA was shown to participate in the base 
pairing to the sRNAs (Figure 6.5).  
 
 
 
 
 
 
 
Figure 6.4 Base-pairing between Qrr sRNAs and hapR and vca0939 mRNAs 
 MFOLD algorithm predictions for mRNA hybrids containing the Qrr sRNA 
sequence fused by a six-base linker (denoted n) to hapR (Qrr/hapR) or 
vca0939 (Qrr/vca0939) mRNA (Hammer and Bassler 2007). 
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Figure 6.5 Base-pairing between Qrr sRNAs and hapR and vca0939 mRNAs 
(Top), Predicted Qrr/vca0939 duplex. (Bottom), The predicted inhibitory stem-
loop structure in the mRNA of vca0939 .In all of the models, the RBSs are 
shown in red, the initiation codons are underlined, and the predicted sRNA 
binding site in the vca0939 mRNA is in blue. 
After analysis of the 5 UTR sequence of the vca0939 mRNA, it was predicted 
that when there is no Qrr sRNAs present, the region overlapping both the 
RBS and the putative sRNA binding site of the vca0939 mRNA forms a single 
inhibitory stem-loop structure. In the reverse situation, when the Qrr sRNA 
interacts with the vca0939 mRNA, the RNA duplex apparently prevents the 
formation of the inhibitory structure and allows the sequence to be accessible 
to the ribosome, promoting translation (Figure 6.5) (Hammer and Bassler 
2007). 
6.3 Cloning, expression and optimization of solubility of VCA0939 
protein 
The target protein VCA0939 from V. cholerae is 321 amino acids long with an 
estimated iso-electric point (pI) of 5.9.The total molecular weight of the protein 
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is 37662.6 and analysis of the protein sequence in the bio-informatics server 
RONN (Yang et al., 2005) showed that in the C-terminal region three residues 
(285-287) predicted to be disordered (Figure 6.6). 
 
Figure 6.6 Disorder prediction of VCA0939 in RONN 
The vca0939 gene was amplified by PCR from genomic DNA of V. cholerae 
O1 El Tor strain N16961 using standard protocols (Section I-5) (Figure 6.7.A). 
Primers (VHBIO, UK) for PCR amplification from genomic DNA contained 
specific recognition sites NcoI in the forward primer (5ʹ′- 
GCAACCCATGGAAAATTGGCTGTC -3ʹ′) and SalI site in the reverse primer 
(5ʹ′- GAGAGGCTAGGTCGACCTTATTCT -3ʹ′). After amplification, the PCR 
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product was digested with the respective enzymes and cloned into the 
similarly digested expression vectors (pEHISTEV, pLOU3 and 
pEHISEGFPTEV) (Section I-3.A and Figure I-1. A-C). After propagation in E. 
coli DH5α strain, the positive clones were picked by colony PCR (Section I-
10.B), (Figure 6.7.A-D). The correct gene was verified by DNA sequencing in 
the University of Dundee (Section I-11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Agarose gel electrophoresis of vca0939 gene products  
(A) Amplification of vca0939 gene from genomic DNA of V. cholerae O1 El 
Tor strain N16961. M, 1 kb DNA ladder (Promega); lane 1-2, Amplification of 
VCA0939 gene products. (B) Positive band for colony PCR for pEHISTEV 
vector. (C) Positive band for colony PCR for pLOU3 vector. (D) Positive band 
for colony PCR for pEHISEGFPTEV vector. 
All of the vectors containing the vca0939 gene were transformed into 
expression host Escherichia coli strain Rosetta (DE3) cells. In order to 
achieve soluble expression of the proteins, the cells were grown at 37 °C at a 
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volume of 10 ml up to an optical density value of 0.5 at λ=600nm. Then the 
cells were subjected to induction with IPTG at a final concentration of 1mM. 
Following induction, the cells were grown for three hours at 37°C (section II-
1). There was no soluble expression of VCA0939 (Figure 6.8).  
The cells were then subjected to various cold and heat shocks and various 
time / temperature incubations (Table 6.1 and Figure 6.9). Because none of 
the shock treatments (table 6.1) induced soluble expression of VCA0939 
protein, auto induction media (Invitrogen) was used to express both of the 
pLOU3 and pEHISEGFPTEV constructs of VCA0939. Unfortunately, no 
soluble expression of VCA0939 was detected (Figure 6.10. A). 
 
 
 
 
 
 
Figure 6.8 Protein expression trial of VCA0939  
M, protein marker (Mark12™, Invitrogen); lane 1, cell lysate after IPTG 
induction “w” stands for whole cell; lane 2, “s” stands for soluble expression. 
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Table 6.1 Conditions used for the induction of soluble expression of VCA0939 
 
 
 
 
 
 
 
 
 
Figure 6.9 Protein expression trial of VCA0939 
M, protein marker (Mark12™, Invitrogen); “w” stands for whole cell; “s” stands 
for soluble expression. 
6.3 Denaturation and renaturation of VCA0939 protein 
Denaturation of VCA0939 by denaturation buffer (6 M guanidine HCl, 0.1 M 
Tris-HCl pH 8.6, 1 mM EDTA, 0.05M NaCl and 10 mM DDT) brought the 
protein into solution (Figure 6.10.B). The sample was denatured by dissolving 
Expression 
(Shock) 
Expression Host 
(E. coli) 
Incubation 
Temperature 
Incubation 
Time 
Heat shock 
or 
Cold shock 
or 
No shock 
Rosetta (DE3) 
or 
BL21 (DE3) 
25 °C 
or 
18 °C 
Overnight 
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the green pellets in the denaturation buffer with stirring at 4 °C over 24-72 
hours. As the sample became denatured, the green colour started to 
disappear due to GFP unfolding and at the end of the process. Then the 
sample was checked in the gel again and then re dissolved in the renaturation 
buffer. Renaturation of the soluble denatured protein with refolding buffer (50 
mM Tris HCl, pH 8, 1 mM EDTA, 0.25 M NaCl, 0.25M L-arginine and 5 mM 
DTT) was performed in the same way as the denaturation process (4 °C over 
24-72 hours) (Figure 6.10.C) 
 
 
 
 
 
 
 
Figure 6.10 Protein expression trials of VCA0939 
M, protein marker (Mark12™, Invitrogen); VCA0939 is indicated by red 
asterisks; (A) expression trial in Auto induction media, lane 1-2,expressed in 
BL-21 cells, pLOU3 constructs; lane4-7, expressed in Rosetta cells, eGFP 
constructs; “w” stands for whole cell; “s” stands for soluble expression; (B) 
Protein denaturation, (DN = Denatured protein sample, precipitated after 
centrifugation DNS = Denatured protein sample, soluble fraction after 
centrifugation; (C) Checking renaturation of the denatured protein (RN = 
Renatured protein sample) 
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6.4 Large-scale protein Expression and purification 
A transformed expression host colony was used to inoculate 250 ml LB or 
TPB media containing Ampicillin 100 µg/ml followed by shaking incubation at 
37 °C overnight. After incubation, 20 ml culture was inoculated in each of 5 
flasks containing 1000 ml of same media with Ampicillin 100 µg/ml followed by 
shaking incubation at 37°C for 2-3 hours until an OD600 of 0.5-0.6 was 
reached. At this point, cells were exposed to 0.5-1.0 mM of IPTG (isopropyl-
beta-D-thiogalactopyranoside) and the incubator temperature was lowered to 
25 °C. The culture was then incubated at 25 °C for over the night to induce 
the expression of more soluble protein. After over night incubation, cells were 
spun down at 8000 rpm for 20 minutes at 4 °C. The pellet was re-suspended 
in a sufficient amount of buffer (20 mM Tris-HCl, pH 8.0 + 50 mM NaCl and 20 
mM imidazole), DNase (20 µg/ml) and EDTA (Ethylenediamine tetraacetic 
acid) free protease inhibitor (Roche Applied Science) were added to the cell 
suspension and the cells were disrupted by sonication for about 10 minutes at 
4 °C. The sonicated sample was then spun down again at 18000 rpm for 25 
minutes at 4 °C. After centrifugation, the soluble fragment was separated and 
syringe filtered through a 0.22 µm filter unit (Millipore). 
Because, VCA0939 never appeared soluble in the small-scale expression 
trial, it was decided to scale up and purify the denatured protein from the E. 
coli protein contaminants and then re-fold again using refolding buffer. 
However, after expressing the MBP tagged protein (instead of GFP tagged 
version) in large scale and checking the gel during the purification process it 
appeared that the protein expressed solubly, possibly due to better aeration in 
 147	  
large scale (Figure 6.11. A). The protein sample was then purified using two 
steps of Ni-columns followed by a gel filtration chromatography (Figure 6.11. 
B-F). But after the removal of solubilisation partner MBP, the protein 
VCA0939 became very unstable and tended to aggregate (Figure 6.11.F). 
 
 
 
 
 
 
 
Figure 6.11 Protein purification of VCA0939 
M, protein marker (Mark12™, Invitrogen); (A) Checking solubility in large 
scale; lane 1,cell lysate, lane 2,soluble fraction; (B) 1st Ni column purification; 
lane 1, cell lysate after IPTG induction; lane 2, supernatant after sonication; 
lane 3, flow-through (unbound protein) after loading sample in to the column; 
lane 4, column wash with the buffer containing 10 mM imidazole; lane 5-9, 
elution in buffer containing 50-350 mM imidazole. (C) TEV digestion; Lane 1, 
Un-digested sample of VCA0939; Lane 2, TEV digested sample of VCA0939 
(D) 2nd Ni column purification; lane 1,pre-column; lane 2,flow through; lane 3-
5, column wash with the buffer containing 20 mM imidazole; lane 6-10, elution 
in buffer containing 50-350 mM imidazole. (E) Gel filtration chromatogram of 
VCA0939  (F) Gel filtration chromatography of VCA0939. 
Purified VCA0939 was analysed by mass spectrometry, confirming the 
identity of the target protein (Figure 6.3.D). 
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Fractions containing purified VCA0939 were concentrated to 18mg/ml using a 
10,000-Da MWCO centrifugal concentrator (Milipore). Two ml of pure protein 
was obtained, small aliquots of 50 µl of the protein sample were flash frozen 
in liquid nitrogen and stored at -80 °C. The PCT™ (Pre-Crystallization Test 
from Hampton Research) was used to determine the appropriate protein 
concentration for crystallization screening (section IV-1). The ideal 
concentration to crystallize the VCA0939 protein was determined to be 9 
mg/ml. The lower concentration of 9 mg/ml and the higher concentration of 18 
mg/ml of the protein was used for crystal plate set up 
6.5 Protein crystallization 
A Pre-crystallization test (Section IV-1) indicated the appropriate protein 
concentration (9 mg/ml) for crystallization screening. Seven crystal screens 
such as Hampton crystallization screen and Index (Hampton Research), the 
PEGs (Qiagen), CRYO and Wizard I+II (Emerald Biosciences), PACT and 
JCSG+ (Molecular Dimensions).  Crystal plates were initially setup using 
Honeybee crystallization robot (Genomic Solutions) in the SSPF 
(www.sspf.ac.uk) with 150 nl of buffer and 150 nl of protein (Section IV-2). No 
crystals were found to date. Future work plan on this protein is described in 
chapter-7. 
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Chapter 7 
Concluding remarks and future works 
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7. Concluding remarks and future works 
The main purpose of this study was to understand the synthesis of the major 
quorum sensing autoinducer CAI-1 and its interaction with the cognate 
receptor CqsS. The structural study of CqsA was performed successfully with 
some remarkable success in the functional characterization of the enzyme. 
Two potential substrates L-threonine or L-2-amino butyric acid were predicted 
to be involved in the catalysis of CAI-1 synthesis by CqsA in the presence of 
its co-factor pyridoxal phosphate (PLP) and a 10 carbon fatty acyl CoA  
(decanoyl-CoA). The crystal structure containing external aldimine (ternary 
complex) proved the catalysis of reaction by CqsA using L-threonine as a 
substrate. For further confirmation of the result the reaction was optimised in 
large volume (10 ml). Unfortunately because of the volatile nature of CAI-1 
detection of it was not possible by mass spectrometry following chemical 
extraction of the reaction mixture. An azido linked CoA, azidoheptanoyl-CoA 
(called compound-1 in this study) was synthesised to ease the detection of 
CAI-1 in the mass spectrometry. The findings of the study were also published 
in an international journal, Journal of Molecular Biology (Jahan et al., 2009). 
Although another paper (Kelly et al., 2009) was published on the mechanism 
of CAI-1 biosynthesis by CqsA in Nature Chemical Biology (after our 
publication), their finding was not more specific than ours. They also 
concluded with the possibility of either L-2-amino butyric acid as a substrate 
that would require an additional keto-reductase enzyme or the possibility of an 
unknown substrate.  
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In a recent paper (Wei et al, 2011) (S)-adenosylmethionine (SAM) was 
identified as another potential substrate that can synthesize CAI-1 in a more 
efficient way and the catalytic activity of SAM was shown to be better than L-
2-amino butyric acid. They also proposed different schemes of CAI-1 
synthesis using SAM as the substrate. They could not get any crystal 
structure with aldimine complex (vinyl glycine-CqsA binary complex or di-keto 
CAI-1-CqsA binary complex). Therefore it could be exciting to work in the 
future in an attempt to obtain the binary or ternary complex of external 
aldimine to understand the catalytic pathway in a more elaborate and practical 
way. 
The attempt of cloning and expression of CAI-1 receptor CqsS was very 
complicated because of the presence of “gtg” in the genome instead of “atg” 
as the initiation codon. There were lots of difficulties to clone the entire CqsS 
and all of its truncated versions. Problems appeared in every steps from gene 
multiplication (PCR) to the expression of the cloned genome and finally to get 
the proteins in soluble state and purification. Different approaches were 
adopted to clone the genome sequences, site directed mutation was 
performed to eliminate the unwanted termination problem of histidine kinase 
domain and also changing vector for construct-2 and construct-3 solubilize the 
proteins and in case of HKRD domain for better purification of the protein. 
Because the proteins became unstable and started to aggregate after 
cleavage from their solubilisation partner, MBP (maltose binding protein) 
additives had been added during concentration. The expression of entire 
CqsS was more complicated because it is a membrane protein and toxic to 
the expression hosts E. coli BL-21 (DE3), Rosetta and C43 (DE3) and used to 
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cause cell death as soon as they were induced to over express the protein. 
The growth conditions were optimized by lowering the concentration of IPTG 
and incubation to a more tolerable level, that eventually promoted the over 
expression of CqsS over an elongated incubation time of several days. Again 
loading the viscous protein into the gel became complicated due to the 
presence of detergent DDM. The problem was eventually solved by the 
addition of high concentration of NaCl (0.5 M and 1.0 M) and boiling of large 
quantity of protein sample (1.0 ml) prior to loading into the gel that also helped 
the detection of the protein by mass spectrometry that was not possible 
before because of the high background detergent (DDM) signal. Therefore the 
knowledge obtained from the trouble shooting during the cloning, expression 
and purification of entire CqsS and its sub domains will be very helpful to 
purify large quantities of entire CqsS protein for crystallization. Because it is a 
membrane protein and CAI-1 upon binding to it triggers the activation of 
histidine kinase cascade, working through the crystallization of entire CqsS 
would be very exciting in the future. 
Although it was possible to solve the structure of the HKRD fraction of the 
CqsS protein, a more detailed phosphotransferase assay could be done on 
this protein. It would be very exciting to crystallize the phosphorylated HKRD 
protein that will be very useful to explain the conformational changes between 
the domains and residues of the protein due to the phosphorylation process. 
VCA0859 was included in the study in an attempt to identify if this enzyme 
can catalyse the reduction of diketo-CAI-1 to CAI-1. Although the crystal 
structure was solved with success, the catalytic activity of this protein was not 
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enough to satisfy its purpose. To determine the function of this protein, a 
commercial aldehyde screen can be used. Gene knockout experiment can 
also be performed on this protein to find out the change in the colony 
morphology (if there is any), which will be useful to find out its function. 
Because Wei et al has identified VC1059 as the correct enzyme for the 
reduction of diketo-CAI-1 to CAI-1 and was not able to obtain a crystal 
structure of the protein, it would be exciting to work towards the cloning, 
expression and crystallization of VC1059 in future. Some additional assay and 
soaking experiment could also be done with the protein and its crystal using 
synthetic substrate Azidoheptanoyl-CoA and diketo substrate (tridecane-3, 4-
dione) used in this study. 
VCA0939 is a very important quorum regulatory protein and therefore was 
included in this study. The expression of soluble protein was not possible until 
it was cloned into a MBP vector. Again, destabilization and aggregate 
formation started to appear as soon as its solubilization partner MBP was 
cleaved off during the process of purification. Although it was possible to 
concentrate the protein to 18 mg/ml, no crystal has been formed so far. In the 
future several approaches could be taken to increase the stability of the 
protein either changing the purification buffer or thermal shift assay to choose 
a better buffer condition prior to crystallization. Some more commercial 
screens can also be tested to obtain a crystal structure of this important 
protein. 
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Appendix I: Materials and Methods 
I-1 Strains and preparation of genomic DNA 
The strain of V. cholerae used in this experiment is V. cholerae O1 El Tor 
strain N16961 (kindly provided by Dr. E. Fidelma Boyd). Genomic DNA 
(gDNA) was extracted from the bacterial culture by using the Easy-DNA kit 
(Invitrogen) according to the manufacturers’ instructions. The following E. coli 
strains were used as cloning and expression hosts: 
Strain Organism 
C43 (DE3) Escherichia coli 
Tam I Escherichia coli 
BL21 (DE3) Escherichia coli 
Rosetta (DE3) Escherichia coli 
DH5α Escherichia coli 
 
I-1.1 Target proteins 
Initially, two proteins involved in V. cholerae quorum sensing regulatory 
pathway, VCA0523 and VCA0939 were targeted for crystallization. Both of 
them are located in the Vibrio cholerae chromosome II (Table I-1). VCA0523 
is also called the enzyme CqsA that synthesizes the major cholera 
autoinducer CAI-1 and VCA0939 is a GGDEF domain containing protein that 
plays an important role in biofilm formation. Later on, the receptor for CAI-1, 
called CqsS involved in V. choleare quorum sensing regulatory pathway was 
targeted for crystallization. It is a membrane protein that functions as a cell 
surface receptor protein. It has six trans-membrane helices coiled into the lipid 
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bi-layer in the outer membrane of the bacteria followed by the cytoplasmic 
histidine kinase domain and a cytoplasmic receiver domain (Henke and 
Bassler 2004b); both of the cytoplasmic domains are connected by a variable 
region (of about 159 amino acids).The cqsS gene (vca0522) is located in the 
Vibrio cholerae chromosome II. Four constructs were designed for the 
convenience of work (Table I-1.1).  
Finally, another additional protein named aldo-keto reductase (VCA0859) 
from V. choleare was targeted in order to find out if there is any relationship 
between the function of CqsA and Aldo-keto reductase and if the latter 
enzyme can help in the reduction of the product made by CqsA. The target 
proteins were analyzed with the help of bio-informatics tools named “PHYRE” 
and summarized in Table I-1. 
Table I-1 Target proteins in Vibrio cholerae 
ORF Length 
(aa) 
Homologous protein * 
VCA0523 389 PLP dependent amino transferase 
VCA0939 321 GGDEF family protein 
VCA0522 686 Sensor histidine kinase/response regulator LuxN 
VCA0859 307 Aldo/keto reductase family oxidoreductase 
 
* Homology based on BLASTP database analysis. 
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Table I-1.1 The four constructs of CqsS 
Name Region Length 
(Amino acids) 
Length (Nucleotide 
bases) 
Construct-1 Full length 1-686 aa 2060 bp 
Construct-2 histidine kinase 
domain 
173-416 aa 729 bp 
 
Construct-3 histidine kinase 
+receiver domain 
173-686 aa 1541bp 
Construct-4 Receiver domain 564-686 aa 368 bp 
 
I-2. Antibiotics 
Table I-2 The following antibiotics were used 
Antibiotic Stock at Used at 
Kanamycin 50 mg/ml 50 µg/ml 
Ampicillin 100 mg/ml  100 µg/ml 
Chloramphenicol 34 mg/ml 34 µg/ml 
 
I-3 Vectors 
I-3.A pEHISTEV 
A modified pEHISTEV vector (Liu and Naismith 2009) named (pHis_lacZα) 
(Dr Md. Arif Sheikh : personal communication) was used (Figure I-1.A).This 
modified vector has a lacZα  gene down stream of the multiple cloning site, 
that facilitates screening of clone positive colonies by blue-white screening. 
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Figure I-1.A Map of cloning vector pEHISTEV 
I-3.B pLOU3 
The vector pLou3 is an engineered variant of NEB vector pMAL-c2X that has 
an N-terminal 6X His-tag followed by maltose binding protein (MBP) that is 
cleavable using Tobacco Etch Virus (TEV) protease, and a lacZα 
complementation gene present after the MCS (multiple cloning sites) (Dr 
Louise Major, personal communication) (Figure I-1.B). 
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Figure I-1.B Map of cloning vector pLOU3 
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I-3.C pEHISGFPTEV 
pEHISGFPTEV another modified pEHISTEV vector (Liu and Naismith 2009) 
expresses a protein with an N-terminal His-tagged green fluorescent protein 
(GFP) fusion (Figure I-1.C). 
 
Figure I-1.C Map of cloning vector pEHISEGFPTEV 
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Above all three of the vectors have a tobacco etch virus (TEV) protease 
cleavage site that allows for production of protein with only two additional N-
terminal residues and have the same multiple cloning site, which enables 
parallel cloning.  
(D) pWaldo-GFPe 
A standard pET28 (a+) derived GFP-8His-fusion vector was used (kindly 
provided by Dr. Simon Newstead). Because screening the expression of 
membrane proteins is very time consuming using standard protocols, a C-
terminal GFP tag was chosen as it has been shown to be a sensitive folding 
indicator for the over-expression of globular proteins (Waldo et al., 1999). 
When GFP is fused to the C-terminus of over expressed globular proteins, 
over expression in a soluble form allows GFP to fold correctly and become 
fluorescent. However, if the globular protein-GFP fusion is over expressed in 
inclusion bodies then GFP is not fluorescent (Figure I-1.D) (Drew et al., 2001) 
 
 
 
Figure I-1.D Map of cloning vector pWaldo-GFPe 
I-4 Oligonucleotide primer sequences used for PCR  
(i) Forward and reverse primers were designed corresponding to the 5ʹ′ and 
complementary 3ʹ′ ends of target genes with specific recognition sites such as 
NcoI and SalI. 
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Table I-3 Oligonucleotide primer sequences for CqsA (VCA0523), VCA0939 
and VCA0859 
Target 
protein 
Primer 
name 
Primer sequence 
(5ʹ′- 3ʹ′) 
Recogniti
on site 
VCA0523 
NcoI_F 
AGGATATATTGCCATGGACAAGC
CTC 
NcoI 
 VCA0523 VCA0523 
SalI_R 
GCAGTTTTTGTTGTCGACGCATT
TAAC SalI 
VCA0939 
NcoI_F 
GCAACCCATGGAAAATTGGCTGT
C 
NcoI 
 VCA0939 VCA0939 
SalI_R 
GAGAGGCTAGGTCGACCTTATTC
T 
SalI 
 
VCA0859__F 
_EcoRI 
GGCATGAATTCATGCAACAACAA
GCAACCGTACAG EcoRI VCA0859 
 VCA0859__R 
_XhoI 
GTTATCTCGAGTTATGGCACGCC
ATGACCTTG XhoI 
 
(ii) The following primers were designed to amplify the target sequences. For 
each of the forward primers a KpnI endonuclease enzyme cleavage site was 
included. And for each of the reverse primers, there was BamHI cleavage site. 
Table I-4.1 Primer set-1 for vca0522 (for pWaldo-GFPe vector) 
Target protein Primer 
name 
Primer sequence 
(5ʹ′- 3ʹ′) 
Recognition 
site 
Cons1_KpnI_F TGCAGGTACCATGA
TAGTGAGC 
KpnI 
 Full length Cons1_BamHI_R GAAGGGTAGGATCC
CACCCAA BamHI 
Cons2_KpnI_F TGTGGTACCATGAA
CCAAAT CTC 
KpnI 
 (histidine kinase 
domain) Cons2_BamHI_R TCGTTAACCGGGAT
CCAATCGT BamHI 
Cons3_NKpnI_F TGTGGTACCATGAA
CCAAAT CTC 
KpnI 
 
histidine kinase 
+ 
Receiver 
domain 
Cons3_BamHI_R AAGGGTAGGATCCC
ACCCAAG BamHI 
Cons4_NKpnI_F TTGGGTACCATGCG
GCATGA 
KpnI 
 Receiver 
domain Cons4_BamHI_R AAGGGTAGGATCCC
ACCCAA 
BamHI 
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Table I-4.2 Primer set-2 for vca0522 (for pWaldo-GFPe vector) 
Target protein Primer 
name 
Primer sequence 
(5ʹ′- 3ʹ′) 
Recognition 
site 
Full length Cons1_XhoI_F TGCACTCGAGATG
ATAGTGAGC 
XhoI 
 
histidine kinase 
domain 
Cons2_XhoI_F TGTCTCGAGATGA
ACCAAAT CTCT 
XhoI 
 
histidine kinase 
+ 
receiver domain 
Cons3_XhoI _F TGTCTCGAGATGA
ACCAAAT CTCT 
XhoI 
 
 
receiver domain Cons4_XhoI_F TTGCTCGAGATGC
GGCATGA 
XhoI 
 
 
Table I-5 Oligonucleotide primer set-3 for vca0522 (for pLou3 vector) 
Primer 
Name 
Primer sequence 
(5ʹ′- 3ʹ′) 
RE site 
Cons1_F_NcoI CTATGCCATGGCTGTGATAGTGAGC
ATGGATGTAAT 
NcoI 
Cons1_R_BamHI GTATTGGATCCCTACACCCAAGCTG
CCACTTTA 
BamHI 
Hk_F_NcoI ATATGCCATGGCTCGTAACCAAATCT
CTCATGAGAC 
NcoI 
HK_R_BamHI GGATTGGATCCCTAATCGTAACGAG
GAAAGCTCAAT 
BamHI 
Cons3_F_NcoI ATATGCCATGGCTCGTAACCAAATCT
CTCATGAGAC 
NcoI 
Cons3_R_BamHI GTATTGGATCCCTACACCCAAGCTG
CCACTTTA 
BamHI 
Hkrd_F_NcoI ATATGCCATGGCTAGTCGGCATGAA
CGACGTATTT 
NcoI 
Hkrd_R_BamHI GTATTGGATCCCTACACCCAAGCTG
CCACTTTA 
BamHI 
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Table I-6 Oligonucleotide primer set-4 for vca0522 (Long primers for 
construct1) 
 
 
 
Primer 
name 
Primer sequence 
(5ʹ′- 3ʹ′) 
Recognition 
site 
Long primer 1: 
XhoI_F 
5’- GAATCTCGAG ATGGTGATAG 
TGAGCATGGA TGTAATAAAG AG-3’ 
XhoI 
 
Long primer 2: 
XhoI_F 
5’- GAATCTCGAG GTAGTGATAG 
TGAGCATGGA TGTAATAAAG AG-3’ 
XhoI	  
Long primer 3: 
XhoI _F 
5’- GAATCTCGAG GTAATGATAG 
TGAGCATGGA TGTAATAAAG AG-3’ 
XhoI	  
BamHI_R_1 5’ – GGTAGGATCCCACCCAAGCTGCC 
ACTTTATTTAGCAATAC-3’ BamHI 
 
I-5 Polymerase chain reaction (PCR)  
The target genes were amplified by polymerase chain reaction (PCR) from 
genomic DNA of V. cholerae O1 El Tor strain N16961. Forward and reverse 
primers were designed corresponding to the 5ʹ′ and complementary 3ʹ′ ends of 
target genes with specific recognition sites such as XhoI and BamHI. PCRs 
were performed in a volume of 50 µl containing 1 µl of forward primer (50 µM), 
1µl of reverse primer (50 µM), 5 µl PCR buffer (10X), 1.5 µl (300 ng) of DNA, 
which was heated at 70 °C for 5 minutes, 2 µl dNTPs (10 mM), 1 µl pfu 
polymerase, 2 µl of MgCl2 (50mM) and water up to 50 µl. The amplification 
conditions were: pre-incubation at 94 °C for 5 minutes, followed by 30 cycles 
of 94 °C for 1 minute, 58 °C (depending on the primer pair) for 1 minute and 
72 °C for 4 minutes. Before storing at 4 °C samples were heated at 72 °C for 
10 minutes. 
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I-6 Agarose gel electrophoresis 
For a 0.8% Agarose gel, 800 mg of agarose was dissolved in 100 ml 1X Tris-
Acetate-EDTA (TAE) buffer. Solutions were cooled slightly before addition of 
5 µl of 10 mg/ml ethidium bromide and then poured into a mould. DNA 
samples were prepared with 10 µl of gel loading solution being added to 50 µl 
DNA and loaded into wells. 1 kb DNA ladder (Promega), 100 bp or 1 kb was 
used depending on the product size. Gels were run at 80 V for 45-55 minutes.  
I-7 Restriction digestion of PCR products and vector 
The product band of target genes were excised from the gel and purified by 
Gel Extraction Kit (Promega). DNA was eluted in a volume of 50µl. To open 
the specific recognition sites in PCR products and vector, varying amount of 
PCR products and vector DNA (with varying concentration) were digested 
with 1µl of each of the respective Fast Digest enzyme (Fermentas), 2-3 µl of 
10x fast digest buffer (depending on the DNA) a total volume of 20-30 µl was 
incubated at 37 °C for 15 minutes followed by denaturation of the enzyme at 
80 °C for 5 minutes. 
I-8 Ligation 
For ligation of target genes into vectors, 1 µl of T4 DNA ligase (Promega) was 
used to ligate 3:1 molar ratio of insert (digested PCR product) and vector 
(digested vector). Ligation reactions were performed in 10 µl volume of 
ligation mixture containing 1 µl of T4 DNA ligase, 1 µl T4 ligase buffer (10X) 
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and varying amount of DNA and water. Ligations were incubated overnight at 
16 °C. 
I-9 Transformation  
5 µl of ligated DNA was transformed into 100 µl of competent host cells such 
as TamI, by cold shock (in ice 30-40 minutes), followed by a heat shock (in 
water bath 42 °C for 1 minute) and cooling on ice for 3-5 minutes. 400 µl of 
pre-warmed Luria-Bertani (LB) Media was added to the transformation 
reaction, and then incubated at 37 °C for 60-90 minutes. After incubation, the 
cells were spun down at 4000 rpm for 4 minutes and following removal of 
excess LB; cells were re-suspended with the remaining supernatant. These 
transformed cells were plated on LB agar containing appropriate antibiotic and 
incubated at 37 °C overnight. Clone positive colonies were identified either by 
blue-white screening  (that contains the lacZα gene) or colony PCR. 
I-10.A Blue/white colony screening 
The substrate X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) was used to 
screen blue/white colonies on the plate. X-gal can be used by the bacterium if 
it is able to produce β-galactosidase. Cloning hosts such the E. coli DH5α or 
Tam1 strains do not contain the lacZα gene, which is one of the active parts 
of β-galactosidase, and can be complemented by vectors such as 
pHis_lacZα. In the presence of β-galactosidase, X-gal is cleaved into bromo-
4-chloro-3-hydroxyindole followed by oxidization to 5,5'-dibromo-4, 4’-dichloro-
indigo, an insoluble blue product which gives characteristic blue coloured 
colonies on the culture plate. Some constructs of pHis_lacZα cannot 
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complement lacZα gene if there is any disruption in the MCS due to the 
presence of our gene of interest. Transformed cells were spread on an LB 
plate containing 40 µL of 40 mg/mL X-gal, 40 µL of 100 mM IPTG and the 
appropriate antibiotic followed by incubation at 37 °C overnight. As X-gal is 
light sensitive, the stock was always wrapped with aluminium foil.  
 
 
 
 
 
Figure I-2 Positive clone identification by blue-white screening 
I-10.B Colony PCR 
Colonies containing recombinant vector DNA were identified using colony 
PCR screening. Several colonies were randomly picked by sterile toothpick 
and each resuspended in 10 µl water, then the wet toothpick was streaked on 
LB agar containing appropriate antibiotic and allowed to grow at 37 °C 
overnight. The remainder of each suspension was heated at 99 °C for 5 
minutes before cell debris was removed by centrifugation. The cell free lysate 
was used in a PCR reaction containing 5 µl lysate, and 9 µl master mix which 
contained 0.18 µl 10 mM dNTPs, 1.4 µl 10X pfu DNA polymerase buffer, 0.18 
µl pfu DNA polymerase, 0.18 µl 5 µM vector specific forward primer and 0.18 
µl 5 µM vector specific reverse primer and 6.88 µl of water. PCR reactions 
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were carried out at 94 °C for 10 minutes, followed by 30 cycles of 94 °C for 30 
seconds, 48 °C for 30 seconds, 72 °C for 1.5 minutes. Before storage at 4 °C, 
samples were incubated at 72 °C for 10 minutes. Colony PCR was analyzed 
by agarose gel electrophoresis. 
I-11 DNA sequencing 
The correct sequence of cloned constructs was confirmed by sequencing 
using T7 forward/reverse and also internal primer sets (TM forward/reverse, 
HK forward/reverse and RVD forward/reverse) primers. For sequencing, 500 
ng of DNA in 30 µl water was sent to the sequencing service at the School of 
Life Sciences, University of Dundee, Scotland (www.dnaseq.co.uk)  
I-12 Purification of transformed plasmid DNA 
A transformed colony containing the recombinant vector was inoculated in 10 
ml LB containing appropriate antibiotic followed by shaking incubation at 
37 °C overnight. After incubation, cells were spun down at 3000 rpm for 10 
minutes at 4 °C. The pellet was collected and plasmid DNA was purified by 
QIA quick spin protocol (QIAGEN), which elutes plasmid DNA in 50 µl of 
water. 
I-13 Transformation in expression host 
3 µl of each transformed plasmid DNA was transformed into 50 µl of BL21 
(DE3), Rosetta  (DE3) and C43 (DE3) cells using the standard protocol 
described earlier followed by plating out on LB agar containing appropriate 
antibiotic and incubated at 37 °C overnight.  
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Appendix II  
II-1 Protein over-expression in E. coli system 
Purified recombinant plasmid vector was transformed into 50 µl of BL21 (DE3) 
and Rosetta (DE3). A transformed expression host colony was used to 
inoculate 10 ml LB containing appropriate antibiotic followed by shaking 
incubation at 37 °C overnight. After incubation, 200 µl culture was inoculated 
into 10 ml LB containing appropriate antibiotic followed by shaking incubation 
at 37 °C for 2-3 hours until an OD600 of 0.5-0.6 was reached. At this point, 
cells were exposed to 0.5-1.0 mM final concentration of IPTG (isopropyl-beta-
D-thiogalactopyranoside) and incubated at 37 °C for 3 hours or 25 °C over 
night to induce the expression of cloned genes. 
After incubation, 1ml of each cell culture were spun down at 13000 rpm for 5 
minutes at 4 °C. The pellet was re-suspended in 100 µl of Bug buster 
(Novagen) and incubated at room temperature for 15 minutes. 1 µl of lysate 
was added to 10 µl of PBS buffer and used as whole cell protein expression 
sample. The rest of the lysate was spun down at 13000 rpm for 5 minutes. 5 
µl of supernatant was added to 10 µl of PBS and was used as soluble protein 
expression sample. Next, 5 µl of loading buffer of 4X lithium dodecyl sulphate 
(LDS) (Invitrogen) was added to both whole cell and soluble samples followed 
by heating at 99 °C for 4 minutes, then run in SDS-PAGE (sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis).  
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II-2 SDS-PAGE  
Pre-cast 4-12% Nupage gels were set up according to the manufacturers’ 
instruction (Invitrogen). Rigs were filled with 800 ml 1X MES buffer and 1ml of 
antioxidant was added to the upper chamber. Loading buffer, 4X LDS was 
added to the protein samples to dilute followed by denaturation at 99 °C for 4 
minutes and samples were loaded into wells alongside an appropriate 
unstained marker such as Mark12™ standard (Invitrogen). Electrophoresis 
was carried out at 200 V and a current of 115-70 mA for 35 minutes. On 
completion, gels were stained with Coomassie Blue to allow protein detection.  
Table II-1 Conditions used for the induction of expression of CqsS 
 
Expression 
(Shock) 
Expression 
Host 
(E. coli) 
Incubation 
temperature 
Incubation 
time 
IPTG 
concentra
tion 
Heat shock 
or 
Cold shock 
or 
No shock 
Rosetta (DE3) 
or 
BL21 (DE3) 
or 
C43 (DE3) 
37 °C 
or 
25 °C 
or 
16 °C 
3 hours 
or 
24 hours 
or 
72 hours 
1.0 mM 
or 
0.2 mM 
or 
0.02 mM 
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Appendix III. Purification 
III-1 Mass spectrometry 
The desired protein bands were excised from gel and sent to the mass 
spectrometry and proteomics facility in the Centre for Bio molecular Sciences 
at the University of St. Andrews. Tryptic fragments of the protein were 
analysed by MALDI-TOF MS (matrix-assisted laser desorption/ionization-time 
of flight mass spectrometry) and MS/MS (tandem mass spectrometry) using a 
4800 MALDI-TOF/TOF analyser (Applied Bio systems)  
III-2 Large-scale protein Expression and purification 
A transformed expression host colony was used to inoculate 250 ml LB or 
TPB media containing kanamycin 35 µg/ml followed by shaking incubation at 
37 °C overnight. After incubation, 20 ml culture was inoculated in each of 5 
flasks containing 1000 ml of same media with kanamycin 35 µg/ml followed by 
shaking incubation at 37°C for 2-3 hours until an OD600 of 0.5-0.6 was 
reached. At this point, cells were exposed to 0.5-1.0 mM of IPTG (isopropyl-
beta-D-thiogalactopyranoside) and the incubator temperature was lowered to 
25 °C. The culture was then incubated at 25 °C for over the night to induce 
the expression of more soluble protein. Or the temperature could be kept at 
37 °C for next 3-4 hours for the expression of soluble protein depending on 
the results found in the small-scale expression trials.  
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III-2.1 Protein purification  
After over night incubation, cells were spun down at 8000 rpm for 20 minutes 
at 4 °C. The pellet was re-suspended in a sufficient amount of buffer 
(depending on the protein used), DNase (20 µg/ml) and EDTA 
(Ethylenediamine tetraacetic acid) free protease inhibitor  (Roche Applied 
Science) were added to the cell suspension and the cells were disrupted by 
sonication for about 10 minutes at 4 °C. The sonicated sample was then spun 
down again at 18000 rpm for 25 minutes at 4 °C. After centrifugation, the 
soluble fragment was separated and syringe filtered through a 0.22 µm filter 
unit (Millipore). 
III-2.2 Nickel column purification 
The recombinant protein, expressed in E. coli (DE3) cells, contained an N-
terminal 6-histidine tag and was purified using a His Trap™ HP column (GE 
Healthcare). Washing gradually with an increasing concentration of imidazole 
from 10 mM up to 350 mM in wash buffer washed away most of the unwanted 
protein and purified the crude extract enough to cleave the 6Histidine tag for 
later steps in the purification. 
III-2.3 Histidine tag cleavage 
Protein samples were dialysed against 5 litre of buffer containing 1 mM DTT 
(Dithiothreitol). TEV (Tobacco Etch Virus) protease was added into the 
dialysis tube containing histidine-tagged protein (roughly, 1 mg of protease for 
50 mg of protein to be cleaved at 4 °C overnight). The digested protein 
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sample was analysed by SDS-PAGE to check the efficiency of TEV protease 
digestion. Next, the digested sample was dialysed again without the DTT for 
overnight at 4 °C with a buffer change after the first 4 hours. Next morning, 
protein sample was syringe filtered through a 0.22-µm-filter unit (Millipore) and 
loaded into the Nickel column again and the flow through was collected in 
fractions and analysed by SDS-PAGE. Corresponding fractions were pooled 
and concentrated to 5 ml by using a centrifugal concentrator (depending on 
the molecular size of the protein) (Millipore). The concentrated sample was 
used in gel filtration column chromatography for further purification. 
III-2.4 Gel filtration chromatography 
In the final stage of protein purification, 5ml sample was loaded onto a Hi-
prepTM 16/60 SephacrylTM S-200 gel filtration column attached to an AKTA 
purification system (GE Healthcare) according to the manufacturers’ protocol. 
Samples from the observed peaks were analysed separately by SDS-PAGE. 
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Appendix IV. Crystallisation and data collection 
IV-1 Pre crystallisation test 
The protein samples were concentrated to about 8.5 mg/ml (depending on the 
protein) by using appropriate MWCO centrifugal concentrator (Millipore). 
Small aliquots of 50 µl of the sample were made and flash frozen in liquid 
nitrogen and stored at -80 °C. The PCT™ (Pre-Crystallization Test) is used to 
determine the appropriate protein concentration for crystallization screening. 
Sample concentration is a significant crystallization variable. Samples too 
concentrated can result in amorphous precipitate, while too dilute samples 
can result in clear drops. Precipitate and clear drops are typical crystallization 
screen results for reagent conditions, which do not promote crystallization and 
are part of every crystallization screen. However, by optimizing protein 
concentration for the screen, the number of clear and precipitated results can 
often be reduced, which in turn results in more efficient sample utilization 
while at the same time enhancing the chances for crystallization. The ideal 
concentration to crystallize the target protein can be determined by using PCT 
kit (Hampton research) according to the manufacturers’ protocol.  
IV-2 Protein crystallization and optimization 
A total of seven crystal screens were set-up with two different protein 
concentrations. Different commercially available crystallization screens were 
used to screen initial conditions of crystallization, such as Hampton 
crystallization screen and Index (Hampton Research), the PEGs (Qiagen), 
CRYO and Wizard I+II (Emerald Biosciences), PACT and JCSG+ (Molecular 
Dimensions). Crystal plates were initially setup using Honeybee crystallization 
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robot (Genomic Solutions) in the SSPF (www.sspf.ac.uk/) with 150 nl of buffer 
and 150 nl of protein.  
IV-3 X-ray data collection and processing  
A suitable protein crystal was picked out from the drops with a crystal loop 
and transferred to 5µl of cryo-protectant drop (most commonly crystallization 
buffer with 10% glycerol and 10% ethylene glycol). The crystal was then re-
looped and exposed to X-ray at 100K the in-house using a Rigaku/MSC 
MicroMax-007HF rotating anode equipped with a Saturn 944+ CCD detector 
at wavelength 1.54178 Å. at -176 °C. The crystal-to-detector distance, rotation 
angle and other parameters were initially set to measure a 2.7 Å resolution 
data set for preliminary analysis. For further comprehensive data collection, 
the detector was set at different distances based on the diffraction quality of 
the crystal. The crystallization data were indexed and integrated using the 
program MOSFLM (Leslie 1992). The integrated data were merged and 
scaled using the programs of the CCP4 (CCP4. 1994). 
IV-4 Data processing, Structure solution and refinement 
Data were indexed and integrated using the program MOSFLM (Leslie 1992). 
The integrated data were merged and scaled using the programs of the CCP4 
(CCP4. 1994) suite. Structures were solved by molecular replacement using 
PHASER (CCP4. 1994). The structures were refined by cycles of model 
building Coot (Emsley and Cowtan 2004) and refinement using REFMAC, 
CCP4 suite (CCP4. 1994). 
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